,Name_VH,Name_VL,Genbank_protein_id_vh,Genbank_protein_id_vl,Binds_to,Origin,VH,VL,Reference,doi,Description_VH,Description_VL,Date_added
0,D27,D27,7VYR_A,7VYR_B,SARS-CoV-2,Homo sapiens (human),mewswvflfflsvttgvlsqvqlqqsgaevkkpgssvkvsckasggtfgnwsiswvrqapgqglewmggidpsrgeatyaqkfqgrvtittdeststaymelsslrsedtavyycareteqggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhhh,mgikmethsqvfvymllwlsgvegsyeltqppsvsvapgktaritcggnnigrksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvydlfsdyvfgtgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jeong,B.S. et al.; Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants; MAbs 14 (1), 2021601 (2022); 2022.",10.1080/19420862.2021.2021601,"Chain A, D27 heavy chain","Chain B, D27 light chain",2022-03-15
2,DH1042,DH1042,7THT_d,7THT_b,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaylelsslrsedtavyycarymvtrdqyyydmdvwgqgttvtvs,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppptfgqgtklei,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.",10.1101/2022.01.25.477784,"Chain d, DH1042 heavy chain","Chain b, DH1042 light chain",2022-03-15
5,DH1058,DH1058,7TOW_A,7TOW_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgfnfgdfgmhwvrqapgkglewvavisyegrnknhadsvrgrftisrdnsrnmlylqmnslrrgdtavyycakenrdrnydswsasysdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgidrylawyqqkpgsapklliyaastlqsgvpsrfsgsgsetdftltisslqpddfatyycqqlstyptitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.",10.1101/2022.01.25.477784,"Chain A, DH1058 Fab heavy chain","Chain B, DH1058 Fab Light chain",2022-03-15
7,S304,S304,7TN0_M,7TN0_N,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,"Chain M, S304 Fab heavy chain","Chain N, S304 Fab light chain",2022-03-15
9,S309,S309,7TN0_C,7TN0_D,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,"Chain C, S309 heavy chain","Chain D, S309 light chain",2022-03-15
11,S309,S309,7TM0_N,7TM0_O,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,ivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkve,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,"Chain N, S309 Fab Heavy Chain","Chain O, S309 Fab light chain",2022-03-15
14,S2L20,S2L20,7TM0_I,7TM0_H,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvss,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdfk,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,"Chain I, S2L20 Fab heavy chain","Chain H, S2L20 Fab light chain",2022-03-15
18,S309,S309,7TLY_A,7TLY_B,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvs,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.",10.1126/science.abn8652,"Chain A, S309 Fab heavy chain","Chain B, S309 Fab light chain",2022-03-15
19,A5-10,A5-10,7F7E_C,7F7E_L,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaivgsggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycaksliyghydiltgayyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,aqmtqspssvsasvgdrvtipcrasqgignwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfppfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtk,"Wang,F. et al.; Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants; Emerg Microbes Infect 11 (1), 548-551 (2022); 2022.",10.1080/22221751.2022.2032374,"Chain C, Heavy chain of A5-10 Fab","Chain L, Light chain of A5-10 Fab",2022-03-15
20,CC40.8,CC40.8,7SJS_H,7SJS_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Zhou,P. et al.; A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection; Sci Transl Med, eabi9215 (2022) In press; 2022.",10.1126/scitranslmed.abi9215,"Chain H, CC40.8 Fab heavy chain","Chain L, CC40.8 Fab light chain",2022-03-15
21,P36-5D2,P36-5D2,7FAF_g,7FAF_f,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytfttyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycaggggrrlqfdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,mgwsciilflvatatgvhsdiqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyngypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Shan,S. et al.; A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants; Front Immunol 12, 766821 (2021); 2021.",10.3389/fimmu.2021.766821,"Chain g, P36-5D2 heavy chain","Chain f, P36-5D2 light chain",2022-03-15
27,CV503,CV503,7LQ7_H,7LQ7_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"Chain H, CV503 heavy chain","Chain L, CV503 light chain",2022-03-15
28,COVA1-16,COVA1-16,7LQ7_y,7LQ7_z,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"Chain y, COVA1-16 heavy chain","Chain z, COVA1-16 light chain",2022-03-15
33,836H,836L,7EZV_M,7EZV_N,SARS-CoV-2,Homo sapiens (human),mgwslillflvavatrvlsqvqlvqsgpevkkpgtsvrvsckasgftfstsavqwvrqargqrlewigwiavgsgktdylqkfqervtmtrdestntaymqlsslrsedtavyycaaphcsggtcydgfdiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,mgwsciilflvatatgvhseivltqspgtlslspgeratlscrasqsvrsgyfawyqqrpgraprlliygassrataipdrfsgsgsgtdftltinrlepedfavyycqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain M, 836H","Chain N, 836L",2022-03-15
34,BD-804H,BD-804L,7EYA_H,7EYA_L,SARS-CoV-2,Homo sapiens (human),vqlvesggglvkpggslrlscaasgftfsnydmnwvrqapgkglewvssisssstythyadsvkgrftisrdnaknslylqmnslraedtavyycardrayrlgelsslwgddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,vwmtqspsllsastgdrvtvscrmsqdissylawyqqkpgkapelliyaaftlqsgvpsrfsgsgsgteftltisslqsedfatyycqqyysfphtfgqgtklerrrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-804H","Chain L, BD-804L",2022-03-15
35,BD-771H,BD-771L,7EY5_H,7EY5_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggfvkpggslrlscaasgfkfsdawmnwvrqapgkglewvgrikskadgqttdyaapvkgrfsisrddskntlflqihnlesddtavyycttgalvesryfdwftgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqmtqspsslsasvgdrvtitcrtsqgiynylawyqqkpgkvpklliygastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkyksapltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-771H","Chain L, BD-771L",2022-03-15
36,BD-821H,BD-821L,7EY5_B,7EY5_C,SARS-CoV-2,Homo sapiens (human),elqlvqsgaevkkpgeslkisckysgnispnfwigwvrqmagkglewmgiiypddsdsryspsfqgqviisadksittallhwsslkvsdtakyycvygsgspsnwfhpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,evvmtqspatlsvspgeratlscrasqsvrynlawyqqkpgqaprlliydastratgipgrfsgsgsgteftltisslqsedfavyycqqydnwppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain B, BD-821H","Chain C, BD-821L",2022-03-15
37,BD-667,BD-667,7EY4_H,7EY4_L,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgfrfsdyymnwirqapgkglewisyigsggfatyygdsvkgrftvsrddaenslylqmnslraedtavyycargvtsysdnsgnyrtddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,eivmtqspatlsvspgeratlscrasqsvsrnlawyqqrpgqaprlliygastratgvaarftgsgfgteftltisglqsedfavyycqeynnwppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-667 H","Chain L, BD-667 L",2022-03-15
38,BD-813H,BD-813L,7EY0_H,7EY0_L,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpggslrlscaasefivsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyfcarflptydyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrtsqsistylhwyqqkpgkapklliyaasslhsgvpsrfsgsgsgthfvltinglqpedfatyycqhtdttpltffgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, BD-813H","Chain L, BD-813L",2022-03-15
39,BD-744H,BD-744L,7EY0_A,7EY0_B,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgaswnsgtigyadsvkgrfiiirdnaknslylqmnslrsedtasyycakdfsrdgdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,yvlpqppsvsvapgktaritcggnniehksvhwyqqkprqapvvvmyydsdrpsgiperfsgsnsgntatliisrveagdeaeyycqvwdrssdqpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain A, BD-744H","Chain B, BD-744L",2022-03-15
40,NT-193,NT-193,7E5O_H,7E5O_L,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargwdldyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkgsslevlfqgplghhhhhh,airmtqspsamsasvgdrvtvtcrasqgignylawfqlkpgkvpkrliyaasslqsgvparfsgggsgteftltisslqpedfatyyclqhgflpwtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity 54 (10), 2385-2398 (2021); 2021.",10.1016/j.immuni.2021.08.025,"Chain H, NT-193 Heavy chain","Chain L, NT-193 Light chain",2022-03-15
41,RBD-CHAB45,RBD-CHAB45,7F63_H,7F63_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlqqsgpelvkpgasvkiscktsgytfteytiywvkqslgkslewiggnnpnnddttykqffkgkatltvdkssstaymelrsltsedsavyycardgypyyyaldfwgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,divmtqsqkfmstsvgdrvsvtckssqnvgtnvawyqqkpgqspkaliysasyrysgvpdhftgsgsgtdftltisnvqsadlaeyfcqqynnypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.",10.1371/journal.ppat.1009704,"Chain H, RBD-chAb45, Heavy chain","Chain L, RBD-chAb45, Light chain",2022-03-15
42,RBD-CHAB-25,RBD-CHAB-25,7F62_H,7F62_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqleesggglvkpggslklscaasgftfssytmswvrqspekrlewvaeissggtytnypdtatgrftisrdnakntlylemsslrsedtamyycanfgnyeeiaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,qivltqspaimsvslgervtmtctasssvsssylhwyqqkpgsspklwiystsnlasgvparfsgsgsgtsysltissmeaedaatyychqyhrspytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.",10.1371/journal.ppat.1009704,"Chain H, RBD-chAb-25, Heavy chain","Chain L, RBD-chAb-25, Light chain",2022-03-15
43,HB27,HB27,7CYP_I,7CYP_H,SARS-CoV-2,Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Zhu,L. et al.; Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2; Natl Sci Rev 8 (3), nwaa297 (2020); 2021.",10.1093/nsr/nwaa297,"Chain I, Heavy chain of HB27","Chain H, Light chain of HB27",2022-03-15
46,FC08,FC08,7DX4_H,7DX4_L,SARS-CoV-2,Homo sapiens (human),qllqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipiigianyaqkfqgrvtitadkststaymelsslrsedtavyycarergysgygaayyfdywgqgtlvtvssa,svltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvlgq,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.",10.1093/nsr/nwab053,"Chain H, Heavy chain of FC08 Fab","Chain L, Light chain of FC08 Fab",2022-03-15
47,FC05,FC05,7D4G_N,7D4G_G,SARS-CoV-2,Homo sapiens (human),evqlleqsgaevkkpgasvrvsckvsgytlpevamhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatttpfsssywfdpwgqgtlvtvss,qsvltqapsvsgapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.",10.1093/nsr/nwab053,"Chain N, Heavy chain of FC05 Fab","Chain G, Light chain of FC05 Fab",2022-03-15
48,COVA2-39,COVA2-39,7JMP_H,7JMP_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.",10.1016/j.celrep.2020.108274,"Chain H, COVA2-39 heavy chain","Chain L, COVA2-39 light chain",2022-03-15
49,COVA2-04,COVA2-04,7JMO_H,7JMO_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.",10.1016/j.celrep.2020.108274,"Chain H, COVA2-04 heavy chain","Chain L, COVA2-04 light chain",2022-03-15
50,K398.22,K398.22,7TP4_H,7TP4_L,SARS-CoV,Macaca mulatta (Rhesus monkey),evqlaesggglvkpggslrlscvasgftfssnemhwvrqapgkglewvsvisesgftteyadsvkgrftisrdnaknslflqmnslraedtavyyctrvsifgqfivatyfdywgqgvlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qaaltqprsvsgspgqsvtisctgtssdiggynyvswyqqhpgtapklmiyavserpsgvsdrfsgsksgntasltisglqaedeadyyccsyagtvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.",NaN,"Chain H, K398.22 heavy chain","Chain L, K398.22 light chain",2022-03-15
51,K288.2,K288.2,7TP3_H,7TP3_L,SARS-CoV,Macaca mulatta (Rhesus monkey),evrlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgatthytdsvkgrftisrdnaknslflqmnslraedtavyyctrpqsvtvfgvaatsyeafdfwgqglrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divmtqspdtlslspgetatlscrasqsvssyvawyqqkpeqpprlliygsssratgmpdrfsgsgsgtdftltisslepddfavyycqqytnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.",NaN,"Chain H, K288.2 heavy chain","Chain L, K288.2 light chain",2022-03-15
52,FI3A,FI3A,7Q0A_Y,7Q0A_Z,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvs,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdik,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain Y, FI3A fab heavy chain","Chain Z, FI3A fab Light chain",2022-03-15
53,FD-5D,FD-5D,7PR0_G,7PR0_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycaspggitaagtsvlfgyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpitwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain G, FD-5D Fab heavy chain","Chain F, FD-5D Fab light chain",2022-03-15
56,FD-11A,FD-11A,7PQZ_A,7PQZ_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgpdiltgyynyyyygmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain A, FD-11A Fab heavy chain","Chain B, FD-11A Fab light chain",2022-03-15
57,FI-3A,FI-3A,7PQZ_H,7PQZ_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.",10.7150/thno.65563,"Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",2022-03-15
60,S2K146,S2K146,7TAT_F,7TAT_G,not determined,Homo sapiens (human),qvqlvesggvvvqpggslrlscaasgftfhdhtmhwvrqapgkglewvslitwnggtihysdsvkgrftisrdnsknslylqmnslrtedtalyycakdlgrggwylpsdawgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgssanigsntvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvl,"Park,Y.J. et al.; Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry; Science 375 (6579), 449-454 (2022); 2022.",10.1126/science.abm8143,"Chain F, S2K146 Fab heavy chain","Chain G, S2K146 Fab light chain",2022-03-15
64,CV38-142,CV38-142,7LM9_H,7LM9_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkiscqgsgysftsywigwvrqmpgkglewmgiiypgesdtrysssfqghvtisadksistaylqwsslkasdtamyycarirgvyssgwiggdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprqwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.",10.1101/2021.02.11.430866,"Chain H, CV38-142 Fab heavy chain","Chain L, CV38-142 Fab light chain",2022-03-15
66,COVA1-16,COVA1-16,7LM8_H,7LM8_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.",10.1101/2021.02.11.430866,"Chain H, COVA1-16 Fab heavy chain","Chain L, COVA1-16 Fab light chain",2022-03-15
67,COVA1-16,COVA1-16,7JMX_H,7JMX_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,H. et al.; Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity; bioRxiv (2020); 2020.",10.1101/2020.08.02.233536,"Chain H, COVA1-16 heavy chain","Chain L, COVA1-16 light chain",2022-03-15
69,AB-3467,AB-3467,7MSQ_H,7MSQ_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyhwnwirqppgkglewigyiyysgntnynpslksrvsistdtsknqfslklssvtaadtavyycvremrrgysgydywdlyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Burnett,D.L. et al.; Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability; Immunity 54 (12), 2908-2921 (2021); 2022.",10.1016/j.immuni.2021.10.019,"Chain H, AB-3467 Fab Heavy Chain","Chain L, AB-3467 Fab Light Chain",2022-03-15
71,BETA-43,BETA-43,7Q0I_A,7Q0I_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnnfyadsvkgrftisrdnfkntlylqmnslraedtavyycarsycsggfcfgyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgktatitcggnnigtksvhwyqqkpgqapvlviyynsdrpsgiperfsgsnsgntvtltisrveagdeadyycqvwdsgsdhyvfgtgtkvtvvgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-43 heavy chain","Chain B, Beta-43 Fab light chain",2022-03-15
73,BETA-50,BETA-50,7Q0H_A,7Q0H_B,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasrgtfntyvftwvrqapgqglewmggiipffgtadyaqkfqgrvtitaddststaymelsslrsedtavyycsrlsqwdllpmwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsftssylawyqqkpgqaprlliygassratgipdrfsgtgsgtdftltisrlepedfavyycqqygtsprmytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-50 Fab heavy chain","Chain B, Beta-50 Fab light chain",2022-03-15
74,BETA-54,BETA-54,7Q0H_H,7Q0H_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvfggsitssnhywvwirqppgkglewigsmyysgstaynpsltnrvtisvdtsknqfslklssvtaadtavyycarqigpkrpsqvadwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-54 Fab heavy chain","Chain L, Beta-54 Fab light chain",2022-03-15
75,BETA-49,BETA-49,7Q0G_A,7Q0G_B,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-49 Fab heavy chain","Chain B, Beta-49 Fab light chain",2022-03-15
76,FI-3A,FI-3A,7Q0G_H,7Q0G_L,SARS-CoV-2,Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, FI-3A Fab heavy chain","Chain L, FI-3A Fab light chain",2022-03-15
77,BETA-06,BETA-06,7Q9P_J,7Q9P_K,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain J, Beta-06 heavy chain","Chain K, Beta-06 light chain",2022-03-15
80,BETA-53,BETA-53,7Q9M_E,7Q9M_F,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslrisckgsghnspsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslqasdtaiyycarhvvalthlypdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspatlsvspgeratlscrasqsvsstlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwstwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain E, Beta-53 fab heavy chain","Chain F, Beta-53 fab light chain",2022-03-15
83,BETA-32,BETA-32,7Q9K_D,7Q9K_E,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittgymelsslrsddtalyycarvgahdyydssdnwfdpwgqgtlvtvfsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspssvsasvgdrltitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain D, Beta-32 heavy chain","Chain E, Beta-32 light chain",2022-03-15
85,BETA-26,BETA-26,7Q9J_J,7Q9J_K,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgasisnyywswirqppgkglewvgyiyytgstnhnpslksrvtisldtsknqfslrlssvtaadtavyycaraycsggscfdtfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggnnigsksvhwfqqkpgqapvlvvyddsdrpsgiperfsgsnsgntasltisrveagdeadyycqvwdsasdsgvfgtgtkltvpgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain J, Beta-26 heavy chain","Chain K, Beta-26 light chain",2022-03-15
91,COVOX-222,COVOX-222,7Q9G_E,7Q9G_F,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvss,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdik,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain E, COVOX-222 heavy chain","Chain F, COVOX-222 light chain",2022-03-15
96,BETA-40,BETA-40,7PS7_H,7PS7_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgpgqvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgsayynpslksrvtisvdtsknqfslklnsvtaadtavfycarhaapspgdnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsvsvspgqtaritcsgdalstqngnwyqqkpgqapvmvickdserpsgiperfsgsrsgttvtltisgvqaedeadyhcqsadnrahvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-40 heavy chain","Chain B, Beta-40 Fab light chain",2022-03-15
98,BETA-44,BETA-44,7PS6_C,7PS6_D,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwispyngnthyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvvtqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyagskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecsec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain C, Beta-44 Fab heavy chain","Chain D, Beta-44 Fab light chain",2022-03-15
100,BETA-47,BETA-47,7PS5_H,7PS5_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgpemkkpgtsvkvsckasgftfitsavqwvrqargqrlewmgwiavgsgntnyaqkfqdrvtinrdmststaymelsslrsedtavyycaaphcnrtschdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsrnylawyqqkpgqvprlliygassratgipdrfrgsgsgtdftltinrlesedfavyycqqygsslftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-47 Fab heavy chain","Chain L, Beta-47 Fab light chain",2022-03-15
101,BETA-38,BETA-38,7PS4_B,7PS4_C,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsgtryspsfqgqvtisadksirtaylqwsslkasdsamyycarsrvgatggyydyymdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnlggntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain B, Beta-38 Fab heavy chain","Chain C, Beta-38 Fab light chain",2022-03-15
104,BETA-29,BETA-29,7PS2_A,7PS2_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhrvrqapgkglewvalisyeesnryygdsvrgrftisrdnskntlylqmnslrpedtavyycakdqgpatvmvtairgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyfgspsitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-29 Fab heavy chain","Chain B, Beta-29 Fab light chain",2022-03-15
105,BETA-27,BETA-27,7PS1_A,7PS1_B,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgltvrsnymnwvrqapgkglewvsliysggstfyadsvkgrftisrhdskntlylqmnslraedtavyycardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssslawyqqkhgqaprlliygtssratgipdrfsgsgsgtdftltisglepedfavyycqqygssplfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain A, Beta-27 Fab heavy chain","Chain B, Beta-27 Fab light chain",2022-03-15
106,BETA-24,BETA-24,7PS0_B,7PS0_C,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpglvkpsqtlsltcsvsdgsisssdyywswirqppgkglewigyiyytgstyynpslksrvsisvdrsknqfslklssvtaadtavyycarlvvpspkgswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqpasvsgspgqsitisctgtsidvgnynlaswyqqhpgkapkliiyegsrrpsgvsnrfsgaksgntasltisglqaedeadyyccsyvgsstyvfgsgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain B, Beta-24 heavy chain","Chain C, Beta-24 light chain",2022-03-15
108,BETA-22,BETA-22,7PRZ_H,7PRZ_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgkglewvavisydgshkyyadsvkgrftisrdnskntlylqmnslktedtavyycakdssaaipyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqmtqspdslavslgeratinckssqsilynsnnktylawyqqkpgqppkllifwastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiplifgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain H, Beta-22 Fab heavy chain","Chain L, Beta-22 Fab light chain",2022-03-15
109,BETA-6,BETA-6,7PRY_C,7PRY_D,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain C, Beta-6 Fab heavy chain","Chain D, Beta-6 Fab light chain",2022-03-15
110,COVOX-45,COVOX-45,7PRY_F,7PRY_G,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.",10.1016/j.chom.2021.11.013,"Chain F, COVOX-45 Fab heavy chain","Chain G, COVOX-45 Fab light chain",2022-03-15
114,BETA-49,BETA-49,7Q6E_J,7Q6E_K,not determined,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Afonine,P.V. et al.; Real-space refinement in PHENIX for cryo-EM and crystallography; Acta Crystallogr., Sect. D: Biol. Crystallogr. 74, 531 (2018); 2021.",NaN,"Chain J, Beta-49 heavy chain","Chain K, Beta-49 light chain",2022-03-15
117,CV3-25,CV3-25,7NAB_A,7NAB_B,SARS-CoV,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Zhou,P. et al.; A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes; bioRxiv (2021); 2021.",10.1101/2021.03.30.437769,"Chain A, CV3-25 Fab Heavy Chain","Chain B, CV3-25 Fab Light Chain",2022-03-15
119,LY-COV1404,LY-COV1404,7MMO_D,7MMO_E,SARS-CoV-2,Homo sapiens (human),xitlkesgptlvkptqtltltctfsgfslsisgvgvgwlrqppgkalewlaliywdddkryspslksrltiskdtsknqvvlkmtnidpvdtatyycahhsistifdhwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,qsaltqpasvsgspgqsitisctatssdvgdynyvswyqqhpgkapklmifevsdrpsgisnrfsgsksgntasltisglqaedeadyycssyttssavfgggtkltvlgrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Westendorf,K. et al.; LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants; bioRxiv (2022); 2021.",10.1101/2021.04.30.442182,"Chain D, LY-CoV1404 Fab heavy chain","Chain E, LY-CoV1404 Fab light chain",2022-03-15
121,WRAIR-2151,WRAIR-2151,7N4M_H,7N4M_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgprlvkpsetlsltctvsggsisgsnyfwgwirqppgkglewigtiyyggstyynpslksrvtisvdtsenqfslklssvtaadtavyycanlawlrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsvsltisglktedeadyycqsydssnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2151 antibody Fab heavy chain","Chain L, WRAIR-2151 antibody Fab light chain",2022-03-15
122,WRAIR-2125,WRAIR-2125,7N4L_H,7N4L_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslrpedtavyycakdspyyydssgyypgyfqdwgqgslvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasigdrvtitcrasqtisdylnwyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2125 antibody Fab heavy chain","Chain L, WRAIR-2125 antibody Fab light chain",2022-03-15
123,WRAIR-2173,WRAIR-2173,7N4J_H,7N4J_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsgdsisssdyswgwirqppgkglewigtiyyikntyynpslrsrvtlsvdtsknlfslklssvtaadtavyycarerppfdvvvvpaarpynwfdpwglgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvlmqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgskvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2173 antibody Fab heavy chain","Chain L, WRAIR-2173 antibody Fab light chain",2022-03-15
124,WRAIR-2057,WRAIR-2057,7N4I_H,7N4I_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfisywiawvrqmpgkglewmgiiypgdsdttyspsfqgqvtisadksistaylqwsslkasdtaiyycarllyysdsspldswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqshstprtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.",10.1038/s41590-021-01068-z,"Chain H, WRAIR-2057 Antibody Fab Heavy Chain","Chain L, WRAIR-2057 Antibody Fab Light Chain",2022-03-15
125,P22A-1D1,P22A-1D1,7CHS_H,7CHS_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyyclhlnsyrtfglgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,"Chain H, antibody P22A-1D1 heavy chain","Chain L, antibody P22A-1D1 light chain",2022-03-15
126,P5A-3C8,P5A-3C8,7CHP_H,7CHP_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsfiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqehgmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkke,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnsyppgytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,"Chain H, antibody P5A-3C8 heavy chain","Chain L, antibody P5A-3C8 light chain",2022-03-15
127,P5A-1D2,P5A-1D2,7CHO_B,7CHO_C,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstyyadsvkgrftisrdnsnntlylqmnslraedtavyycaralqvgatsdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqscdsslsvvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.",10.1038/s41467-021-24514-w,"Chain B, antibody P5A-1D2 heavy chain","Chain C, antibody P5A-1D2 light chain",2022-03-15
129,SARS2-38,SARS2-38,7MKL_H,7MKL_L,SARS-CoV-2,Mus musculus (house mouse),qvqlkesgpglvapsqslsitctvsgfsltrygvhwvrqppgkglewlgviwadgstyynsalmsrlsiskdnsksqvflnmnslqtddtakyycardgrgyddywgqgttlt,qivltqspaimsaspgekvtmtcsasstvsfiywyqqkpgssprlliydtsnpasgvpvrfsgsgcgtsyyltisrmeaedaatyycqqwntypltfgagtklel,"VanBlargan,L. et al.; A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope; bioRxiv (2021); 2021.",10.1101/2021.04.26.441501,"Chain H, SARS2-38 Fv heavy chain","Chain L, SARS2-38 Fv light chain",2022-03-15
131,P2C-1A3,P2C-1A3,7CDJ_H,7CDJ_L,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardfshqqlvpswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.",10.1038/s41467-020-20501-9,"Chain H, antibody P2C-1A3 heavy chain","Chain L, antibody P2C-1A3 light chain",2022-03-15
132,P2C-1F11,P2C-1F11,7CDI_H,7CDI_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyhcardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.",10.1038/s41467-020-20501-9,"Chain H, antibody P2C-1F11 heavy chain","Chain L, antibody P2C-1F11 light chain",2022-03-15
133,EY6A,EY6A,6ZDG_F,6ZDG_G,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.",10.1038/s41594-020-0480-y,"Chain F, EY6A heavy chain","Chain G, EY6A light chain",2022-03-15
145,2-36,2-36,7N5H_J,7N5H_K,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,"Wang,P. et al.; A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses; bioRxiv (2021); 2021.",10.1101/2021.10.13.464307,"Chain J, 2-36 Fab heavy chain","Chain K, 2-36 Fab light chain",2022-03-15
148,7D6,7D6,7EAM_C,7EAM_D,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgaelvrpgasvklsctasgfnikdtyihwvkqrpeqglewigridpgdgdteydpsfqgkatitadtssntaylelssltsedtavyyctrfydyvdygmdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkiepr,diqmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgsyycqhfwstppwtfgggtklevkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnn,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.",10.1038/s41467-021-25997-3,"Chain C, the heavy chain of Fab fragment of antibody 7D6","Chain D, the light chain of Fab fragment of antibody 7D6",2022-03-15
150,6D6,6D6,7EAN_H,7EAN_L,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgaelvkpgasvklscttsgfniidtymhwvkqrpeeglewiggidpvngnseydpkfqdkatitadtssntaylhlsrltsedtavyycasahyygssssfpywgqgtdlvtvsakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsspwpsetvtcnvahpasstkvdkkivprg,divmtqsqkfmstsvgdrvsvtckasqnvgthvawyqqkpgqspkaliysasyrysgvpdrftgsgvgtdftltitnvqsedlaeyfcqqynsyftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.",10.1038/s41467-021-25997-3,"Chain H, Heavy chain of SARS-CoV-2 cross-neutralizing mAb 6D6","Chain L, Light chain of SARS-CoV-2 cross-neutralizing mAb 6D6",2022-03-15
151,XG014,XG014,7V2A_I,7V2A_H,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfsnywigwvrhmpgkglewmgiiypgdsdtryspsfqgqvtisvdtsistaylqwsslkasdtamyyctrhqygynygyfyyyidvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsaapgqkvtiscsgsssnignnpvswyrqvpgtapklliydnnkrpsgipdrfsgsksgasatlgitglqtgdeadyycgtwhtslssgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.",10.1007/s13238-021-00871-6,"Chain I, The heavy chain of XG014","Chain H, The light chain of XG014 Fab",2022-03-15
154,XG005,XG005,7V26_e,7V26_f,SARS-CoV,Homo sapiens (human),qvtlresgptlvkpkqtltltctfsgfslstpgggvgwirqppgkalewlaliywdddkryspslkssltitkdtsknqvvltmtnmdpvdtatyycarltaadtifdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspglsitisctatssdvgaynyvswyqqhpgqapklmiydvskrpsgvsnrfsgsksantasltisglqaedeadyycssytttsvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.",10.1007/s13238-021-00871-6,"Chain e, XG005 Heavy chain","Chain f, XG005 Light Chain",2022-03-15
157,P5C3,P5C3,7P40_I,7P40_H,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.",10.1016/j.celrep.2021.109814,"Chain I, Variable Heavy Chain P5C3 (VH)","Chain H, Variable Light Chain P5C3 (VL)",2022-03-15
160,GH12-FAB,GH12-FAB,7D6I_B,7D6I_C,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyyctragwvrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhhhh,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Shi,R. et al.; A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2; Unpublished; 2021.",NaN,"Chain B, Heavy chain of GH12-Fab","Chain C, Light chain of GH12-Fab",2022-03-15
161,N-612-004,N-612-004,7S0E_H,7S0E_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyymhwvrqapgkglewvsaisgsggytyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdhaydwgfdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqwadwpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain H, N-612-004 Fab heavy chain","Chain L, N-612-004 Light Chain",2022-03-15
162,N-612-014,N-612-014,7S0D_O,7S0D_P,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamtwvrqapgkglewvsyisgsgggtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrwasgwlafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqayaypltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain O, N-612-014 Fab Heavy Chain","Chain P, N-612-014 Light Chain",2022-03-15
165,N-612-017,N-612-017,7S0C_M,7S0C_N,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaiwgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycargrdlaaftktafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdalpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain M, N-612-017 Fab Heavy Chain","Chain N, N-612-017 Light Chain",2022-03-15
167,N-612-056,N-612-056,7S0B_C,7S0B_D,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvslisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlwgsgffafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqdagtpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.",10.1101/2021.09.14.460356,"Chain C, N-612-056 Fab Heavy Chain","Chain D, N-612-056 Light Chain",2022-03-15
169,2H04,2H04,7K9K_H,7K9K_L,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evqlqqsgaelvkpgasvkmsckasgytftsywitwvkqrpgqglewigdiypgsgstkynekfrseatltvdtssttaymqlssltsedsavyycarwdfygsrtfdywgqgttltvssa,divltqspailsvspgervsfscrasqnigtiihwyqqrtngsprllikyasesvsgipsrfsgsgsgtdftlsinsvesediadyycqqssswpltfgagtklel,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.",10.1016/j.celrep.2021.109881,"Chain H, 2H04 heavy chain","Chain L, 2H04 light chain",2022-03-15
173,2B04,2B04,7K9I_H,7K9I_L,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),qvqlkqsgpglvapsqslsitctvsgfslinyaiswvrqppgkglewlgviwtgggtnynsalksrlsiskdnsksqvflkmnslqtddtaryycarkdyygryygmdywgqgtsvtvs,qavvtqesalttspgetvtltcrsstgavttsnyanwvqekpdhlftgliggtnnrapgvparfsgsligdkaaltitgaqtedeaiyfcalwynnhwvfgggtkltvl,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.",10.1016/j.celrep.2021.109881,"Chain H, 2B04 heavy chain","Chain L, 2B04 light chain",2022-03-15
176,C118,C118,7RKV_G,7RKV_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,"Chain G, C118 Fab Heavy Chain","Chain L, C118 Fab Light Chain",2022-03-15
179,C022,C022,7RKU_J,7RKU_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsvtctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaayydrsgyyfieyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,diqmtqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynnyrytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,"Chain J, C022 Antibody Fab Heavy Chain","Chain L, C022 Antibody Fab Light Chain",2022-03-15
183,C118,C118,7RKS_I,7RKS_M,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapt,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.",10.1016/j.celrep.2021.109760,"Chain I, C118 Antibody Fab Heavy Chain","Chain M, C118 Antibody Fab Light Chain",2022-03-15
185,NCOV617,NCOV617,7E3O_H,7E3O_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyadsvkgrftisrdnskntlylqmnslraedtavyycarglglrflewpissywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkllifsnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Chen,S.D. et al.; Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617; Unpublished; 2021.",NaN,"Chain H, nCoV617 Heigh Chain","Chain L, nCoV617 Light Chain",2022-03-15
186,58G6,58G6,7E3L_D,7E3L_E,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnyaqkfqervtltrdmstrtaymelsslrsedtavyycaapncnsttchdgfdiwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfavyycqqydnspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.",10.1038/s41467-021-26539-7,"Chain D, 58G6 heavy chain","Chain E, 58G6 light chain",2022-03-15
189,13G9,13G9,7E3K_H,7E3K_L,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsgsavqwvrqargqrlewigwivvgsgntnyaqrfqervtitrdmststaymelsslrsedtavyycaapycsstscrdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,T. et al.; Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Nat Commun 12 (1), 6304 (2021); 2021.",10.1038/s41467-021-26539-7,"Chain H, 13G9 heavy chain","Chain L, 13G9 light chain",2022-03-15
192,5-7,5-7,7RW2_I,7RW2_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain; bioRxiv (2021); 2021.",10.1101/2021.06.29.450397,"Chain I, 5-7 heavy chain","Chain K, 5-7 light chain",2022-03-15
196,AB1,AB1,7E3C_B,7E3C_C,SARS-CoV-2,Homo sapiens (human),evllvesggglvqpggslrlscaasgltvssnymtwvrqapgkglewvsviysggstfyadsvkgrctisrhnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppltfgggsrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,"Chain B, Heavy chain of Ab1","Chain C, Light chain of Ab1",2022-03-15
197,AB5,AB5,7E3B_B,7E3B_C,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwtdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnipftfglgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,"Chain B, Heavy Chain of Ab5","Chain C, Light Chain of Ab5",2022-03-15
198,AB4,AB4,7E39_C,7E39_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaretvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,niqmtqspsamsasvgdrvtitcrarqgisnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgseteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.",10.1038/s41421-021-00292-z,"Chain C, Heavy Chain of Ab4","Chain B, Light Chain of Ab4",2022-03-15
199,S2X259,S2X259,7RAL_H,7RAL_L,not determined,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvys,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvl,"Tortorici,M.A. et al.; Broad sarbecovirus neutralization by a human monoclonal antibody; Nature 597 (7874), 103-108 (2021); 2021.",10.1038/s41586-021-03817-4,"Chain H, S2X259 Fab heavy chain","Chain L, S2X259 Fab light chain",2022-03-15
203,C548,C548,7R8O_O,7R8O_P,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarreaygprdyyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsaltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadqgsgsnfvgvfgggtkltvgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain O, C548 Fab Heavy Chain","Chain P, C548 Fab Light Chain",2022-03-15
206,C051,C051,7R8N_O,7R8N_P,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqaggslrlscaasgfgvrnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycaregdvegfsdlwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqpasvsgspgqsitfsctgtssdvggynyvswyqqypgkapklliydvtnrpsgvsdrfsgsksgntasltisglqaedeadyycssftssntrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain O, C051 Fab Heavy Chain","Chain P, C051 Fab Light Chain",2022-03-15
209,C032,C032,7R8M_H,7R8M_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",2022-03-15
211,CR3022,CR3022,7R8L_C,7R8L_D,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain C, CR3022 Fab heavy chain","Chain D, CR3022 Fab light chain",2022-03-15
212,C099,C099,7R8L_H,7R8L_L,SARS-CoV-2,Homo sapiens (human),vqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrg,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",2022-03-15
213,C098,C098,7N3I_H,7N3I_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C098 Fab heavy chain","Chain L, C098 Fab light chain",2022-03-15
214,C032,C032,7N3E_H,7N3E_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C032 Fab Heavy Chain","Chain L, C032 Fab Light Chain",2022-03-15
215,C099,C099,7N3H_H,7N3H_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C099 Fab Heavy Chain","Chain L, C099 Fab Light Chain",2022-03-15
217,C080,C080,7N3F_H,7N3F_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslnisckasgysftiywiawvrqlpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwrslkasdsavyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtiscagsssnigagfdvywyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssgsvlsdlyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.",10.1101/2021.03.07.434227,"Chain H, C080 Fab Heavy Chain","Chain L, C080 Fab Light Chain",2022-03-15
218,B1-182.1,B1-182.1,7MM0_H,7MM0_L,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveirrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.",10.1126/science.abh1766,"Chain H, B1-182.1 Fab heavy chain","Chain L, B1-182.1 Fab light chain",2022-03-15
220,A23-58.1,A23-58.1,7LRT_D,7LRT_E,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.",10.1126/science.abh1766,"Chain D, antibody A23-58.1 heavy chain","Chain E, antibody A23-58.1 light chain",2022-03-15
224,REGN10985,REGN10985,7M42_D,7M42_C,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.",10.1016/j.cell.2021.06.002,"Chain D, REGN10985 antibody Fab fragment heavy chain","Chain C, REGN10985 antibody Fab fragment light chain",2022-03-15
225,REGN10989,REGN10989,7M42_B,7M42_A,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.",10.1016/j.cell.2021.06.002,"Chain B, REGN10989 antibody Fab fragment heavy chain","Chain A, REGN10989 antibody Fab fragment light chain",2022-03-15
226,S2D106,S2D106,7R7N_H,7R7N_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggpfsssaiswvrqapgqglewmggiipmvgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardsrycsggscysvwfdpwgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvemk,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain H, S2D106 FAB heavy chain","Chain L, S2D106 FAB light chain",2022-03-15
227,S2E12,S2E12,7R6X_C,7R6X_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain C, Monoclonal antibody S2E12 Fab heavy chain","Chain D, Monoclonal antibody S2E12 Fab light chain",2022-03-15
228,S309,S309,7R6X_A,7R6X_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain A, Monoclonal antibody S309 Fab heavy chain","Chain B, Monoclonal antibody S309 Fab light chain",2022-03-15
229,S304,S304,7R6X_H,7R6X_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain H, Monoclonal antibody S304 Fab heavy chain","Chain L, Monoclonal antibody S304 Fab light chain",2022-03-15
230,S2X35,S2X35,7R6W_H,7R6W_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.",10.1038/s41586-021-03807-6,"Chain H, Heavy Chain of Fab domain of monoclonal antibody S2X35","Chain L, Light Chain of Fab domain of monoclonal antibody S2X35",2022-03-15
232,S2L20,S2L20,7N8I_H,7N8I_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvs,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdf,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.",10.1126/science.abi7994,"Chain H, S2L20 Fab Heavy Chain Variable Region","Chain L, S2L20 Fab Light Chain Variable Region",2022-03-15
234,S2M11,S2M11,7N8H_M,7N8H_L,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtv,ivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkv,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.",10.1126/science.abi7994,"Chain M, S2M11 Fab Heavy Chain variable region","Chain L, S2M11 Fab Light Chain variable region",2022-03-15
239,COVOX-75,COVOX-75,7ORB_E,7ORB_F,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain E, COVOX-75 Fab heavy chain","Chain F, COVOX-75 Fab light chain",2022-03-15
240,COVOX-253,COVOX-253,7ORB_C,7ORB_D,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain C, COVOX-253 Fab heavy chain","Chain D, COVOX-253 Fab light chain",2022-03-15
247,COVOX-278,COVOX-278,7OR9_H,7OR9_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifirygiswvrqapgqglewmgwisanngytnyaqklqgrvtmttdtststaymelrslrsddtavyycardggiltgyldyfdhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrltitcrasqsiasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystlgitfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain H, COVOX-278 Fab heavy chain","Chain L, COVOX-278 Fab light chain",2022-03-15
248,COVOX-222,COVOX-222,7OR9_A,7OR9_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.",10.1016/j.cell.2021.06.020,"Chain A, COVOX-222 Fab heavy chain","Chain B, COVOX-222 Fab light chain",2022-03-15
255,2B11,2B11,7E5Y_C,7E5Y_B,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaseitvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnsentlylqmnslraedtavyycardlmevggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,lpvltqppsasgtpgqrvtiscsgsssnvendnvnwfqqqvpgstpklviyndrlrpsgvpdrfsgsksgtsaylaisglqsedeadyycvawdaslqsyvfgtgtkvtvlrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pan,Y.B. et al.; Screening of potent and broadly neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries; Unpublished; 2021.",NaN,"Chain C, 2B11 Fab Heavy chain","Chain B, 2B11 Fab Light chain",2022-03-15
257,368-2,368-2,7E8F_C,7E8F_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngylyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain C, 368-2 H","Chain B, 368-2 L",2022-03-15
258,N9,N9,7E8F_H,7E8F_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaaseftfssysmnwvrqapgkglewvssisssgsqiyyadsvkgrftisrdnakkslylqmnslrvedtavyycatnggahsstwsfygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvspgqtatitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltiggtqamdeaayfcqawdsntgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain H, N9 H","Chain L, N9 L",2022-03-15
265,BD-515,BD-515,7E88_J,7E88_K,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtgvyycardrglvsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapkllifdashletgvpsrfsasgsgtdftftisslqpediatyychqydnlprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain J, BD-515 Fab Heavy Chain","Chain K, BD-515 Fab Light Chain",2022-03-15
269,BD-508,BD-508,7E86_A,7E86_B,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlflqmnslraedtavyycardaqnygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllifaasslqtgapsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain A, BD-508 Fab Heavy Chain","Chain B, BD-508 Fab Light Chain",2022-03-15
270,BD-623,BD-623,7E7Y_C,7E7Y_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsavysggstyyadsvkgrftisrhnskntlylqmkslrpedtaiyycarlinhyydssgdggafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ltqpasvsgspgqsitisctgtssdvgsynlvswyqqrpgkapklilyevtkrpsgvsnrfsgsksgntaslaisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvap,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain C, BD-623 Fab H","Chain D, BD-623 Fab L",2022-03-15
272,N11,N11,7E7X_M,7E7X_N,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckvsgytlieisihwvrqapgkglewmggfdpeagetiyaqkfqgrvtmtedtstdtaymevsslrsedtavyycatgpaiaaaetnwfdlwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvtkrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain M, N11 Fab heavy chain","Chain N, N11 Fab Light chain",2022-03-15
274,HB27,HB27,7CYH_E,7CYH_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Wang,X. et al.; Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27; Unpublished; 2021.",NaN,"Chain E, Heavy chain of HB27","Chain D, Light chain of HB27",2022-03-15
275,B6,B6,7M55_H,7M55_L,SARS-CoV,Mus musculus (house mouse),evqlqqsgpvlvkpgasvrmsckasgytitdyylnwvkqshgkslewlgvlnpysggslysqtfkgkatltvdrssstaylelnsltsedsavyycarqlgrgngldywgqgtsvtvssvstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,nimmtqspsslavsagekvtmsckssqsvlhssdqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvqaedlavyfchqylssytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Sauer,M.M. et al.; Structural basis for broad coronavirus neutralization; Nat Struct Mol Biol 28 (6), 478-486 (2021); 2021.",10.1038/s41594-021-00596-4,"Chain H, B6 antigen binding fragment (Fab) heavy chain","Chain L, B6 antigen binding fragment (Fab) light chain",2022-03-15
279,3D11,3D11,7M7B_H,7M7B_L,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.",10.1016/j.cell.2021.04.033,"Chain H, Antibody Fab 3D11 heavy chain","Chain L, Antibody Fab 3D11 light chain",2022-03-15
280,5A6,5A6,7M71_H,7M71_L,SARS-CoV-2,Homo sapiens (human),qvqlqesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycarlitmvrgedywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsslsasvghrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsynlprtfgggtklevlgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.",10.1016/j.cell.2021.04.033,"Chain H, Antibody 5A6 Fab heavy chain","Chain L, Antibody 5A6 Fab light chain",2022-03-15
283,3D11,3D11,7KQE_I,7KQE_N,not determined,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Goddard,T.D. et al.; UCSF ChimeraX: Meeting modern challenges in visualization and analysis; Protein Sci 27 (1), 14-25 (2018); 2021.",10.1002/pro.3235,"Chain I, Fab 3D11 heavy chain","Chain N, Fab 3D11 light chain",2022-03-15
286,47D11,47D11,7AKD_H,7AKD_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsisshywswirqppgkglewigyiyysgstnhnpslksrvtisvdtsknqfslklssvtaadtavyycargvllwfgepifeiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastrapgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkvei,"Fedry,J. et al.; Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11; Sci Adv 7 (23) (2021); 2021.",10.1126/sciadv.abf5632,"Chain H, 47D11 neutralizing antibody heavy chain","Chain L, 47D11 neutralizing antibody light chain",2022-03-15
291,CV2-75,CV2-75,7M3I_H,7M3I_L,SARS-CoV-2,Homo sapiens (human),xvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jennewein,M.F. et al.; Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects; Cell Rep 36 (2), 109353 (2021); 2021.",10.1016/j.celrep.2021.109353,"Chain H, CV2-75 Fab Heavy chain","Chain L, CV2-75 Fab Light chain",2022-03-15
293,47D1,47D1,7MF1_H,7MF1_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvrvsckasggtfstypiswvrqapgqglewmggiipifgtaksaqkfqgrvtitadeftstaymemsslrsedtamyycaregrrygsgwyistgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qlvltqpasvsgspgqsiivsctgtssdvggykfvswyqqhpgkaprvmiydvsnrpsgvsnrfsgsksgntasltisglqaddeadyycssytnsstvvfgggtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhou,X. et al.; Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2; Cell Rep 35 (6), 109109 (2021); 2021.",10.1016/j.celrep.2021.109109,"Chain H, 47D1 Fab heavy chain","Chain L, 47D1 Fab light chain",2022-03-15
294,S2H97,S2H97,7M7W_E,7M7W_F,SARS-CoV-2,Homo sapiens (human),qvrlvqsgaevkksgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistvylqwsslkasdtamyycarqwshytydyyywgqgtlvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqpasvsgspgqsitisctgissdvggynsvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstppyvfgtgtkvsvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.",10.1101/2021.04.06.438709,"Chain E, Monoclonal antibody S2H97 Fab heavy chain","Chain F, Monoclonal antibody S2H97 Fab light chain",2022-03-15
295,S2X259,S2X259,7M7W_H,7M7W_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvysastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.",10.1101/2021.04.06.438709,"Chain H, Monoclonal antibody S2X259 Fab heavy chain","Chain L, Monoclonal antibody S2X259 Fab light chain",2022-03-15
298,BG1-24,BG1-24,7M6I_M,7M6I_N,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriismfgiannaqkfqgrltitadtststaymelsslrsedtavyycargpyyydsggyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvgsgylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagsprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain M, BG1-24 Fab Heavy Chain","Chain N, BG1-24 Fab Light Chain",2022-03-15
300,BG7-20,BG7-20,7M6H_E,7M6H_G,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkagasvkvsckasgytftsydinwvrqasgqglewmgwmnpisgntgyaqkfqgrvtmtrntsittaymelsslrsedtavyfcarggrycssttcysgvgmdvwgqgttvtvpsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyhqlpgtapkfliygnsnrpsgvpdrfsgsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain E, BG7-20 Fab Heavy Chain","Chain G, BG7-20 Fab Light Chain",2022-03-15
302,BG7-15,BG7-15,7M6G_R,7M6G_S,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyaiswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtstntaymelrslrsddtaiyycaipyssvtfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvsgtflawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain R, BG7-15 Fab Heavy Chain","Chain S, BG7-15 Fab Light Chain",2022-03-15
304,BG1-22,BG1-22,7M6F_H,7M6F_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsvsgftvssnymnwvrqapgkglewvsviypggstfypdsvkgrftisrddskntlylqmnslrpedtaayycassrppigqlvpgldldwfdpwgqgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqhpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain H, BG1-22 Fab Heavy Chain","Chain L, BG1-22 Fab Light Chain",2022-03-15
306,BG10-19,BG10-19,7M6E_H,7M6E_L,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartqwgynygshffymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsasgtpgqrvtiscsgsssnigsdhvywyqqlpgtapklfiyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain H, BG10-19 Fab Heavy Chain","Chain L, BG10-19 Fab Light Chain",2022-03-15
309,BG4-25,BG4-25,7M6D_H,7M6D_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvvrnymtwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntmylqmnslraedtaiyycardlevvgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygspmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain H, BG4-25 Fab Heavy Chain","Chain L, BG4-25 Fab Light Chain",2022-03-15
310,CR3022,CR3022,7M6D_A,7M6D_B,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.",10.1016/j.cell.2021.04.032,"Chain A, CR3022 Fab Heavy Chain","Chain B, CR3022 Fab Light Chain",2022-03-15
311,2-15,2-15,7L57_H,7L57_L,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitv,saltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlg,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,"Chain H, Fab 2-15 variable domain heavy chain","Chain L, Fab 2-15 variable domain light chain",2022-03-15
312,H4,H4,7L58_H,7L58_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvpycsstschrdwyfdlwgrgtlvt,diqmtqsplslpvtpgepasiscrssqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpltfgggtkvei,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,"Chain H, Fab H4 variable domain heavy chain","Chain L, Fab H4 variable domain light chain",2022-03-15
313,2-43,2-43,7L56_J,7L56_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.",10.1016/j.celrep.2021.108950,"Chain J, Fab 2-43 variable domain heavy chain","Chain L, Fab 2-43 variable domain light chain",2022-03-15
316,2-17,2-17,7LQW_H,7LQW_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain H, 2-17 Heavy Chain","Chain L, 2-17 Light Chain",2022-03-15
317,5-24,5-24,7L2F_I,7L2F_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain I, 5-24 heavy chain","Chain K, 5-24 light chain",2022-03-15
320,4-18,4-18,7L2E_I,7L2E_K,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain I, 4-18 heavy chain","Chain K, 4-18 light chain",2022-03-15
323,1-87,1-87,7L2D_H,7L2D_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain H, 1-87 heavy chain","Chain L, 1-87 light chain",2022-03-15
324,2-51,2-51,7L2C_C,7L2C_D,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.",10.1016/j.chom.2021.03.005,"Chain C, 2-51 heavy chain","Chain D, 2-51 light chain",2022-03-15
326,4-8,4-8,7LQV_Y,7LQV_Z,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Cerutti,G. et al.; Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite; Cell Host Microbe (2021); 2021.",NaN,"Chain Y, 4-8 Heavy Chain","Chain Z, 4-8 Light chain",2022-03-15
329,2-7,2-7,7LSS_H,7LSS_L,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,salaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.",10.1101/2021.02.21.432168,"Chain H, Fab 2-7 variable heavy chain","Chain L, Fab 2-7 variable light chain",2022-03-15
330,1-57,1-57,7LS9_E,7LS9_G,SARS-CoV-2,Homo sapiens (human),evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.",10.1101/2021.02.21.432168,"Chain E, 1-57 Fab heavy chain","Chain G, 1-57 Fab light chain",2022-03-15
333,DH1041,DH1041,7LAA_H,7LAA_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtfssywmswvrqapgkglewvanirqdgsekysvdsvkgrftisrdnaknslylqmnslraedtavyycararradnsgyygfhfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsdsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain H, DH1041 heavy chain","Chain L, DH1041 light chain",2022-03-15
334,DH1052,DH1052,7LAB_H,7LAB_L,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycatssgpsrlcgggscyhsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,ltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqg,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain H, DH1052 heavy chain","Chain L, DH1052 light chain",2022-03-15
337,DH1047,DH1047,7LD1_H,7LD1_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvqvscqasantftnhyihwvrqapgqglewmgiiyptggntiyaqgfqgrvtmtrdtslntiylelsslrsedtavyycardvrvddswsgydllsggtyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,divmtqspdslavslgeratincrssqsvlyssnnenylawyqqkpgqppklliywastresgipdrfsgsgsgtdftltisrlqaedvavyycqqyyslprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain H, DH1047 heavy chain","Chain L, DH1047 light chain",2022-03-15
340,DH1050.1,DH1050.1,7LCN_M,7LCN_S,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkglewmggfhpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgspfgvvtdwfdpwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnpyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain M, DH1050.1 heavy chain","Chain S, DH1050.1 light chain",2022-03-15
343,CV05-163,CV05-163,7LOP_H,7LOP_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarevmvrgalppygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants; Science 373 (6556), 818-823 (2021); 2021.",10.1126/science.abh1139,"Chain H, CV05-163 Fab heavy chain","Chain L, CV05-163 Fab light chain",2022-03-15
347,MW06,MW06,7DPM_J,7DPM_K,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggstyyadsvrgrftisrdnskntlylqmnslraedtavyccakgyyydssgyyfredafdiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsamsasvgdrvtitcrasqgisnylawfqqkpgkvpkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jiang,W. et al.; Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV; MAbs 13 (1), 1953683 (2021); 2021.",10.1080/19420862.2021.1953683,"Chain J, heavy chain of MW06","Chain K, light chain of MW06",2022-03-15
351,15033-7,15033-7,7KML_J,7KML_N,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqshtypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.",10.1101/2020.10.31.362848,"Chain J, Fab 15033-7 heavy chain","Chain N, Fab 15033-7 light chain",2022-03-15
358,CR3022-B6,CR3022-B6,7KZB_A,7KZB_B,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqsiysalnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtdihpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.",10.1080/19420862.2021.1922134,"Chain A, Fab heavy chain of CR3022-B6 antibody","Chain B, Fab light chain of CR3022-B6 antibody",2022-03-15
359,CR3014-C8,CR3014-C8,7KZB_H,7KZB_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycargispfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqyiydslnwyqqkpgkapklliydssylqsgvpsrfsgsgsgtdftltisslqpedfatyycqqswdtpvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.",10.1080/19420862.2021.1922134,"Chain H, Fab heavy chain of CR3014-C8 antibody","Chain L, Fab light chain of CR3014-C8 antibody",2022-03-15
366,LY-COV481,LY-COV481,7KMI_A,7KMI_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarevagtydywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpggtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,"Chain A, LY-CoV481 Fab heavy chain","Chain B, LY-CoV481 Fab light chain",2022-03-15
367,LY-COV488,LY-COV488,7KMH_A,7KMH_B,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarspyggnswgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,"Chain A, LY-CoV488 Fab heavy chain","Chain B, LY-CoV488 Fab light chain",2022-03-15
368,LY-COV555,LY-COV555,7KMG_D,7KMG_E,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.",10.1126/scitranslmed.abf1906,"Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",2022-03-15
370,2G12,2G12,7L09_M,7L09_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkaggslilscgvsnfrisahtmnwvrrvpggglewvasistsstyrdyadavkgrftvsrddledfvylqmhkmrvedtaiyycarkgsdrlsdndpfdawgpgtvvtvspastkgpsvfplapsxxxxxxxxgtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,dvvmtqspstlsasvgdtititcrasqsietwlawyqqkpgkapklliykastlktgvpsrfsgsgsgteftltisglqfddfatyhcqhyagysatfgqgtrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Acharya,P. et al.; A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies; bioRxiv (2020); 2020.",10.1101/2020.06.30.178897,"Chain M, 2G12 heavy chain","Chain L, 2G12 light chain",2022-03-15
378,NaN,NaN,7B3O_H,7B3O_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrddskntlylqmnslraedtavyycardvadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscaaahhhhhh,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglrspvtksfnrgec,"Bertoglio,F. et al.; A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations; Biorxiv (2020); 2020.",NaN,"Chain H, Heavy Chain of Fab Fragment","Chain L, Light Chain of Fab Fragment",2022-03-15
379,C1A-C2,C1A-C2,7KFX_H,7KFX_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscavsgftvsnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsafvgdrvtitcrasegissylawyqqkpgnapklliyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, heavy chain of human antibody C1A-C2 Fab","Chain L, light chain of human antibody C1A-C2 Fab",2022-03-15
380,C1A-B3,C1A-B3,7KFW_H,7KFW_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, heavy chain of antibody C1A-B3 Fab","Chain L, light chain of antibody C1A-B3 Fab",2022-03-15
383,C1A-F10,C1A-F10,7KFY_H,7KFY_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlengvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, heavy chain of human antibody C1A-F10 Fab","Chain L, light chain of human antibody C1A-F10 Fab",2022-03-15
384,NaN,NaN,7CJF_A,7CJF_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycardlqelgsldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqeansfpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Guo,Y. et al.; A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes; Nat Commun 12 (1), 2623 (2021); 2020.",10.1038/s41467-021-22926-2,"Chain A, antibody heavy chain","Chain B, antibody light chain",2022-03-15
385,S2A4,S2A4,7JVC_F,7JVC_G,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain F, S2A4 Fab heavy chain","Chain G, S2A4 Fab light chain",2022-03-15
388,S2H13,S2H13,7JV6_F,7JV6_G,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdsvqpggslrlscaaagftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycalssgysgyagnywgqgtlvtvss,qavvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgarpedeaeyycllsysgargvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain F, S2H13 Fab heavy chain","Chain G, S2H13 Fab light chain",2022-03-15
391,S304,S304,7JX3_H,7JX3_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain H, Heavy chain of Fab domain of monoclonal antibody S304","Chain L, Light chain of Fab domain of monoclonal antibody S304",2022-03-15
392,S2H14,S2H14,7JX3_C,7JX3_D,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain C, Heavy chain of Fab domain of monoclonal antibody S2H14","Chain D, Light chain of Fab domain of monoclonal antibody S2H14",2022-03-15
393,S309,S309,7JX3_A,7JX3_B,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain A, Heavy chain of Fab domain of monoclonal antibody S309","Chain B, Light chain of Fab domain of monoclonal antibody S309",2022-03-15
394,S304,S304,7JW0_G,7JW0_F,"SARS-CoV-2, Spike protein",Homo sapiens (human),vqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain G, S304 Fab heavy chain","Chain F, S304 Fab light chain",2022-03-15
397,S2A4,S2A4,7JVA_H,7JVA_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.",10.1016/j.cell.2020.09.037,"Chain H, S2A4 Fab heavy chain","Chain L, S2A4 Fab light chain",2022-03-15
402,S2X35,S2X35,7JXE_H,7JXE_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.037,"Chain H, S2X35 antigen-binding (Fab) fragment","Chain L, S2X35 antigen-binding (Fab) fragment",2022-03-15
405,S2H14,S2H14,7JXC_H,7JXC_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.037,"Chain H, S2H14 antigen-binding (Fab) fragment","Chain L, S2H14 antigen-binding (Fab) fragment",2022-03-15
406,C121,C121,7K8X_E,7K8X_G,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispvsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaraplfptgvlagdyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,"Chain E, C121 Fab Heavy chain","Chain G, C121 Fab Light chain",2022-03-15
408,C144,C144,7K90_O,7K90_P,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsnnymswvrqapgkglewvsviysggstyyadsvkgrftisrdkskntlylqmnrlraedtavyycaregevegyndfwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain O, C144 Fab Heavy Chain","Chain P, C144 Fab Light Chain",2022-03-15
411,C135,C135,7K8Z_M,7K8Z_N,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain M, C135 Fab Heavy Chain","Chain N, C135 Fab Light Chain",2022-03-15
414,C119,C119,7K8W_N,7K8W_S,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqklqgrvtmtrdtststvymelsslrsedtavyycaranhettmdtyyyyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqrhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsvvfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain N, C119 Fab Heavy Chain","Chain S, C119 Fab Light Chain",2022-03-15
416,C110,C110,7K8V_M,7K8V_N,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain M, C110 Fab Heavy Chain","Chain N, C110 Fab Light Chain",2022-03-15
418,C104,C104,7K8U_H,7K8U_L,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlslscavyggslsgyywswirqppgkglewigeinhfgstgynpslksrvtisvdtsksqfsvklssvtaadtavyycarkpllysnlspgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtvslspgeratlscwasqsvsasylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygttprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain H, C104 Fab Heavy Chain","Chain L, C104 Fab Light Chain",2022-03-15
419,C002,C002,7K8T_O,7K8T_P,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegrpsdivvvvafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain O, C002 Fab Heavy Chain","Chain P, C002 Fab Light Chain",2022-03-15
425,C102,C102,7K8M_A,7K8M_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,"Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",2022-03-15
426,C135,C135,7K8R_H,7K8R_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.",10.1038/s41586-020-2852-1,"Chain H, C135 Fab Heavy Chain","Chain L, C135 Fab Light Chain",2022-03-15
428,C110,C110,7K8P_H,7K8P_L,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsgptaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain H, C110 Fab Heavy Chain","Chain L, C110 Fab Light Chain",2022-03-15
430,C102,C102,7K8N_A,7K8N_B,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapssksxxxxtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.",10.1038/s41586-020-2852-1,"Chain A, C102 Fab Heavy Chain","Chain B, C102 Fab Light Chain",2022-03-15
431,S2E12,S2E12,7K4N_F,7K4N_G,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvss,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.",10.1126/science.abe3354,"Chain F, S2E12 neutralizing antibody Fab fragment (heavy chain)","Chain G, S2E12 neutralizing antibody Fab fragment (light chain)",2022-03-15
435,S2M11,S2M11,7K43_F,7K43_G,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtvss,eivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.",10.1126/science.abe3354,"Chain F, S2M11 Fab fragment (heavy chain)","Chain G, S2M11 Fab fragment (light chain)",2022-03-15
438,S2E12,S2E12,7K3Q_H,7K3Q_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science (2020) In press; 2020.",10.1126/science.abe3354,"Chain H, Fab fragment of S2E12 monoclonal antibody, heavy chain","Chain L, Fab fragment of S2E12 monoclonal antibody, light chain",2022-03-15
439,CC12.3,CC12.3,6XC7_C,6XC7_D,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.06.08.141267,"Chain C, CC12.3 heavy chain","Chain D, CC12.3 light chain",2022-03-15
443,CC12.1,CC12.1,6XC2_X,6XC2_Y,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.06.08.141267,"Chain X, CC12.1 heavy chain","Chain Y, CC12.1 light chain",2022-03-15
447,G2,G2,6PXH_H,6PXH_L,MERS-CoV,Mus musculus (house mouse),qvqlqqsggelvkpgasvklscktsgftfsssyiswlkqkpgqslewiawiyagtggteynqkftgkaqvtvdtssstaymqfsslttedsaiyycarggssfamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,qlvltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllihtasnqgsgvparfsgsgsgtdfslnihpvedddtamyfcqqseevpltfgagtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,N. et al.; Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD; Cell Rep 28 (13), 3395-3405 (2019); 2019.",10.1016/j.celrep.2019.08.052,"Chain H, G2 heavy chain","Chain L, G2 light chain",2022-03-15
456,G4,G4,5W9O_H,5W9O_I,MERS-CoV,Mus musculus (house mouse),qvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.",10.1073/pnas.1707304114,"Chain H, G4 VH","Chain I, G4 VL",2022-03-15
480,G4,G4,5VZR_A,5VZR_B,MERS-CoV,Mus musculus (house mouse),xvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.",10.1073/pnas.1707304114,"Chain A, G4 antibody heavy chain","Chain B, G4 antibody light chain",2022-03-15
482,S3H3,S3H3,7WDF_F,7WDF_G,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),qvqlqqpgaelvrpgasvklsckasgysftrfwmnwvkqrpgqglewigmihpsdsetrlnqkfkdkatltvdkssttaymqlssptsedsavyycarkdydydawfaywgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divltqspaslavslgqratiscrasksvsasvysymhwyqqkpgqppklliylasslesgvparfsgsgsgtdftlnihpveeedaatyychhsrelppafgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.",10.1080/22221751.2021.2024455,"Chain F, Heavy chain of S3H3 Fab","Chain G, Light chain of S3H3 Fab",2022-03-15
488,S5D2,S5D2,7WD7_e,7WD7_f,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgqslewigginpniddttynqnfkdkatltvdkssstaymefrsltfddsavyycarddkasfafwgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divmsqspsslavsdgervtltckssqsllystnqknylawyqqkpgqspklliywassresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypltfgagtklelradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.",10.1080/22221751.2021.2024455,"Chain e, Heavy chain of S5D2 Fab","Chain f, Light chain of S5D2 Fab",2022-03-15
495,R40-1G8,R40-1G8,7SC1_P,7SC1_Q,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe 30 (1), 69-82 (2022); 2022.",10.1016/j.chom.2021.12.010,"Chain P, R40-1G8 Fab heavy chain","Chain Q, R40-1G8 Fab light chain",2022-03-15
498,COVOX-158,COVOX-158,7QNY_H,7QNY_L,not determined,Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain H, COVOX-158 heavy chain","Chain L, COVOX-158 light chain",2022-03-15
499,COVOX-58,COVOX-58,7QNY_A,7QNY_B,not determined,Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqppgkglewvsgvswnsgtigyadsvkgrfiisrdnaknslylqmnslkaedtalyycarevggtfgvlisreggldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggntigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrvvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain A, COVOX-58 heavy chain","Chain B, COVOX-58 light chain",2022-03-15
500,BETA-55,BETA-55,7QNX_A,7QNX_B,not determined,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisssryywgwirqppgkglewigtfyysgityynpslksrvtifvdtsknqfslklssvtaadtavyycarprppdyydnsgallfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspstlsasvgdrvtiacrasqsisawlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpddfatyycqqyissspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain A, Beta-55 heavy chain","Chain B, Beta-55 light chain",2022-03-15
501,EY6A,EY6A,7QNX_H,7QNX_L,not determined,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.",10.1101/2021.12.03.471045,"Chain H, EY6A heavy chain","Chain L, EY6A light chain",2022-03-15
504,C1C-A3,C1C-A3,7SN3_H,7SN3_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),mkrglccvlllcgavfvspsasqvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,mkrglccvlllcgavfvspsaseivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain; Science 375 (6578), eabl6251 (2022); 2021.",10.1126/science.abl6251,"Chain H, neutralizing antibody C1C-A3 heavy chain variable region","Chain L, neutralizing antibody C1C-A3 light chain variable region",2022-03-15
509,AB1,AB1,7MJK_H,7MJK_I,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain H, Fab ab1 Heavy Chain","Chain I, Fab ab1 Light Chain",2022-03-15
515,CA521,CA521,7E23_B,7E23_C,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2; Commun Biol 4 (1), 500 (2021); 2021.",10.1038/s42003-021-02029-w,"Chain B, CA521 Heavy Chain","Chain C, CA521 Light Chain",2022-03-15
516,P008_056,P008_056,7NTC_H,7NTC_L,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsevqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksgtkhhhhhh,mgwsciilflvatatgvhcairmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Rosa,A. et al.; SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity; Sci Adv (2021) In press; 2021.",10.1126/sciadv.abg7607,"Chain H, P008_056 Fab Heavy chain","Chain L, P008_056 Fab Light chain",2022-03-15
517,S2M28,S2M28,7LY3_F,7LY3_E,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,syeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapte,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain F, S2M28 Fab Heavy Chain","Chain E, S2M28 Fab Light Chain",2022-03-15
519,S2M28,S2M28,7LY2_N,7LY2_O,SARS-CoV-2,Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvs,yeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltv,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain N, S2M28 Fab Heavy Chain variable region","Chain O, S2M28 Fab Light Chain variable region",2022-03-15
526,S2L28,S2L28,7LXZ_N,7LXZ_O,SARS-CoV-2,Homo sapiens (human),evqlvesggglvnpggslrlscaasgftfsdytihwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslslqmnslraedtavyycardgnaykwllaenvrfdywgqgtlvtvss,vtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsdrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpnwvfgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain N, S2L28 Fab Heavy Chain variable region","Chain O, S2L28 Fab Light Chain variable region",2022-03-15
532,S2X333,S2X333,7LXY_N,7LXY_O,SARS-CoV-2,Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnsknslylqmnslraedtavyfcarafpdssswsgftidywgqgtlvtv,yeltqppsvstaritcggnnierksvhwcqqkpgqapalvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdqvifgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.",10.1016/j.cell.2021.03.028,"Chain N, S2X333 Fab Heavy Chain variable region","Chain O, S2X333 Fab Light Chain variable region",2022-03-15
552,DH1043,DH1043,7LJR_S,7LJR_T,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgssvkvsckasggtfsryainwvrqapgqglewmgriipifgianyaqkfqgkvtitadkststaymelsslrsedtavyycaradyyydssgyffdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshytqkslslspgk,mgwsciilflvatatgvhseivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqtprlliygassratgiparfsgsgsgtnftltisrlepedfavyycqqysssrtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.",10.1101/2020.12.31.424729,"Chain S, Fab DH1043 heavy chain","Chain T, Fab DH1043 light chain",2022-03-15
553,CR3022,CR3022,6ZH9_HHH,6ZH9_LLL,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapssggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.",10.1038/s41594-020-0469-6,"Chain HHH, CR3022 heavy","Chain LLL, CR3022 Light chain",2022-03-15
554,P5A-3C12,P5A-3C12,7D0D_G,7D0D_F,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslfltvgyssswspfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain G, Heavy chain of P5A-3C12","Chain F, Light chain of P5A-3C12",2022-03-15
556,P5A-3A1,P5A-3A1,7D0C_G,7D0C_F,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain G, Heavy chain of P5A-3A1","Chain F, Light chain of P5A-3A1",2022-03-15
559,COVOX-269,COVOX-269,7NEH_H,7NEH_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Supasa,P. et al.; Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera; Cell 184 (8), 2201-2211 (2021); 2021.",10.1016/j.cell.2021.02.033,"Chain H, COVOX-269 Fab heavy chain","Chain L, COVOX-269 fab light chain",2022-03-15
561,COVOX-159,COVOX-159,7NDD_H,7NDD_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsevqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnryyadsvkgrftisrdnskntlylqmnrlraedtamyycakdrddgwdwyyfmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspgtlslspgeratlscrasqsisgnylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-159 Fab heavy chain","Chain L, COVOX-159 Fab light chain",2022-03-15
567,COVOX-253H165L,COVOX-253H165L,7NDB_H,7NDB_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygasrrgtgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-253H165L Fab heavy chain","Chain L, COVOX-253H165L Fab light chain",2022-03-15
568,COVOX-253H55L,COVOX-253H55L,7NDA_H,7NDA_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-253H55L Fab heavy chain","Chain L, COVOX-253H55L Fab light chain",2022-03-15
570,COVOX-384,COVOX-384,7ND8_H,7ND8_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsevqlvesggglvkpgeslrlscaasgftfsdyymtwirqapgkglewvsyirssghtiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarggvlrflewplnafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynnalgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-384 Fab heavy chain","Chain L, COVOX-384 Fab light chain",2022-03-15
571,COVOX-316,COVOX-316,7ND7_J,7ND7_K,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain J, COVOX-316 Fab heavy chain","Chain K, COVOX-316 Fab light chain",2022-03-15
574,COVOX-158,COVOX-158,7ND6_H,7ND6_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-158 Fab heavy chain","Chain L, COVOX-158 Fab light chain",2022-03-15
575,COVOX-150,COVOX-150,7ND5_H,7ND5_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiysggttyyadsvkgrftisrdssmntlylqmnslraedtavyycardlmvygidvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhseivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqldsyppgytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-150 Fab heavy chain","Chain L, COVOX-150 Fab light chain",2022-03-15
576,COVOX-88,COVOX-88,7ND4_F,7ND4_G,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqlqlqesgpglvkpsqtlsltctvsggsissgsynwtwirqpagkglewigriynsgstnynpslksrvtisvdtsknqlslkvrsvtaadtavyycarhcsggtcypkyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgswaqsaltqppsvseaprqrvtiscsgsssnignnavnwyqqfpgkapklliyyddllpsgvsdrfsgsksgtsaslaisgvqsedeadyycaawddslnvvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain F, COVOX-88 Fab heavy chain","Chain G, COVOX-88 Fab light chain",2022-03-15
579,COVOX-40,COVOX-40,7ND3_H,7ND3_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesggglvqpggslrlscavsgftvsrnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfhrsgyhdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsviwmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkllifdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpafgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-40 heavy chain","Chain L, COVOX-40 light chain",2022-03-15
580,S309,S309,7BEP_G,7BEP_I,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain G, S309 heavy chain","Chain I, S309 light chain",2022-03-15
584,COVOX-75,COVOX-75,7BEO_E,7BEO_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain E, COVOX-75 heavy chain","Chain F, COVOX-75 light chain",2022-03-15
585,COVOX-253H55L,COVOX-253H55L,7BEO_C,7BEO_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain C, COVOX-253H55L heavy chain","Chain D, COVOX-253H55L light chain",2022-03-15
588,COVOX-75,COVOX-75,7BEN_G,7BEN_I,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain G, COVOX-75 heavy chain","Chain I, COVOX-75 light chain",2022-03-15
589,COVOX-253,COVOX-253,7BEN_D,7BEN_F,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain D, COVOX-253 heavy chain","Chain F, COVOX-253 light chain",2022-03-15
592,COVOX-269,COVOX-269,7BEM_H,7BEM_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastggsggggsggggsgg,gasaiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikaaalvprgssawshpqfekggsgggsggsawshpqfek,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-269 Vh domain","Chain L, COVOX-269 Vl domain",2022-03-15
594,COVOX-45,COVOX-45,7BEL_C,7BEL_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain C, COVOX-45 heavy chain","Chain D, COVOX-45 light chain",2022-03-15
600,COVOX-316,COVOX-316,7BEH_H,7BEH_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsqavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.",10.1016/j.cell.2021.02.032,"Chain H, COVOX-316 heavy chain","Chain L, COVOX-316 light chain",2022-03-15
601,H014,H014,7CAC_E,7CAC_D,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnrgec,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2021.",10.1126/science.abc5881,"Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",2022-03-15
607,H014,H014,7CAH_E,7CAH_D,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleil,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2020.",10.1126/science.abc5881,"Chain E, Heavy chain of H014 Fab","Chain D, Light chain of H014 Fab",2022-03-15
608,S304,S304,7L0N_M,7L0N_N,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Thomson,E.C. et al.; Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity; Cell 184 (5), 1171-1187 (2021); 2021.",10.1016/j.cell.2021.01.037,"Chain M, Monoclonal antibody S304 Fab heavy chain","Chain N, Monoclonal antibody S304 Fab light chain",2022-03-15
612,2-15,2-15,7L5B_H,7L5B_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Biorxiv (2021); 2021.",NaN,"Chain H, 2-15 Heavy chain","Chain L, 2-15 Light Chain",2022-03-15
613,910-30,910-30,7KS9_H,7KS9_L,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycariygdyawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsrsgtdftftisslqpediatyychqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Banach,B.B. et al.; Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses; bioRxiv (2021); 2021.",10.1101/2020.12.31.424987,"Chain H, 910-30 Fab heavy chain","Chain L, 910-30 Fab light chain",2022-03-15
614,LY-COV555,LY-COV555,7L3N_D,7L3N_E,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection; bioRxiv (2020); 2021.",10.1101/2020.09.30.318972,"Chain D, LY-CoV555 Fab heavy chain","Chain E, LY-CoV555 Fab light chain",2022-03-15
615,P17,P17,7CWL_I,7CWL_K,SARS-CoV,Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssas,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res 31 (1), 25-36 (2021); 2021.",10.1038/s41422-020-00444-y,"Chain I, Fab P17 heavy chain","Chain K, Fab P17 light chain",2022-03-15
619,H014,H014,7CWN_O,7CWN_M,SARS-CoV,Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.",10.1038/s41422-020-00444-y,"Chain O, heavy chain of H014 Fab","Chain M, light chain of H014 Fab",2022-03-15
620,P17,P17,7CWN_G,7CWN_F,SARS-CoV,Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.",10.1038/s41422-020-00444-y,"Chain G, heavy chain of P17 Fab","Chain F, light chain of P17 Fab",2022-03-15
628,CC12.3,CC12.3,7KN7_H,7KN7_L,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain H, CC12.3 Fab heavy chain","Chain L, CC12.3 Fab light chain",2022-03-15
630,NaN,NaN,7CM4_H,7CM4_L,not determined,Homo sapiens (human),qitlkesgptlvkptqtltltcsfsgfslstsgvgvgwirqppgkalewlalidwddnkyhttslktrltiskdtsknqvvltmtnmdpvdtatyycaripgflryrnryyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,elvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggteltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kim,Y.G. et al.; to be publish; Unpublished; 2021.",NaN,"Chain H, IgG heavy chain","Chain L, IgG light chain",2022-03-15
631,2H2,2H2,7DK7_c,7DK7_d,SARS-CoV-2,Mus musculus (house mouse),qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,"Chain c, The heavy chain fragment of 2H2 Fab","Chain d, The light chain fragment of 2H2 Fab",2022-03-15
640,3C1,3C1,7DD8_A,7DD8_B,SARS-CoV-2,Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,"Chain A, The heavy chain of 3C1 fab","Chain B, The light chain of 3C1 chain",2022-03-15
643,3C1,3C1,7DCX_E,7DCX_H,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.",10.1038/s41467-020-20465-w,"Chain E, The heavy chain of 3C1 fab that binds with the up RBD","Chain H, The light chain of 3C1 fab",2022-03-15
649,CV07-250,CV07-250,6XKQ_H,6XKQ_L,SARS-CoV-2,Homo sapiens (human),qvqlvqseaevkepgasvevsckasgynftnfaiswvrqapgqglewmgwisgyngdtnsaqkflgrvtmttdtstttaymelrslrsddtavyycagsdnygfpyngmdvwgqgttvtvfnqikppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtisctgtssdlgayhfvtwyqhypgkapkvmiygvrkrpsgvpdrfsgsksgntasltvsglqdedeadyycssyagnndfvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.",NaN,"Chain H, CV07-250 Heavy Chain","Chain L, CV07-250 Light Chain",2022-03-15
650,CV07-270,CV07-270,6XKP_M,6XKP_N,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymtwirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarargssgwyrigtrwgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssnvvfgggtmltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.",NaN,"Chain M, CV07-270 Heavy Chain","Chain N, CV07-270 Light Chain",2022-03-15
652,BD-368-2,BD-368-2,7CHH_J,7CHH_K,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.035,"Chain J, BD-368-2 Fab heavy chain","Chain K, BD-368-2 Fab light chain",2022-03-15
656,BD-604,BD-604,7CHF_H,7CHF_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-604 Fab heavy chain","Chain L, BD-604 Fab light chain",2022-03-15
658,BD-236,BD-236,7CHE_H,7CHE_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstdyadsvkgrftisrdkskntlylqmnslraedtavyycardlgeaggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-236 Fab heavy chain","Chain L, BD-236 Fab light chain",2022-03-15
660,BD-629,BD-629,7CHC_H,7CH5_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-629 Fab H","Chain L, BD-629 Fab L",2022-03-15
663,2-4,2-4,6XEY_J,6XEY_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Liu,L. et al.; Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike; bioRxiv (2020); 2020.",10.1101/2020.06.17.153486,"Chain J, 2-4 Heavy Chain","Chain L, 2-4 Light Chain",2022-03-15
666,4A8,4A8,7C2L_J,7C2L_N,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatstavagtpdlfdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,eivmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfpytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chi,X. et al.; A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2; Science 369 (6504), 650-655 (2020); 2020.",10.1126/science.abc6952,"Chain J, heavy chain of 4A8","Chain N, light chain of 4A8",2022-03-15
669,CV30,CV30,6XE1_H,6XE1_L,SARS-CoV-2,Homo sapiens (human),xvqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,xivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hurlburt,N.K. et al.; Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation; bioRxiv (2020); 2020.",10.1101/2020.06.12.148692,"Chain H, CV30 Fab Heavy chain","Chain L, CV30 Fab Kappa chain",2022-03-15
670,C105,C105,6XCN_H,6XCN_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssxlyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsasgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.",10.1016/j.cell.2020.06.025,"Chain H, C105 Fab Heavy Chain","Chain L, C105 Fab Light Chain",2022-03-15
675,C105,C105,6XCA_H,6XCA_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsgsgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.",10.1016/j.cell.2020.06.025,"Chain H, C105 Heavy Chain","Chain L, C105 Light Chain",2022-03-15
676,REGN10987,REGN10987,6XDG_C,6XDG_A,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.",10.1126/science.abd0827,"Chain C, REGN10987 antibody Fab fragment heavy chain","Chain A, REGN10987 antibody Fab fragment light chain",2022-03-15
677,REGN10933,REGN10933,6XDG_B,6XDG_D,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.",10.1126/science.abd0827,"Chain B, REGN10933 antibody Fab fragment heavy chain","Chain D, REGN10933 antibody Fab fragment light chain",2022-03-15
678,AB23-FAB-HEAVY,AB23-FAB-LIGHT,7BYR_H,7BYR_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpqggsswyrdyyygmdvwgqgttvtvss,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Cao,Y. et al.; Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells; Cell 182 (1), 73-84 (2020); 2020.",10.1016/j.cell.2020.05.025,"Chain H, Ab23-Fab-Heavy Chain","Chain L, Ab23-Fab-Light Chain",2022-03-15
679,NaN,NaN,7BWJ_H,7BWJ_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Ju,B. et al.; Human neutralizing antibodies elicited by SARS-CoV-2 infection; Nature 584 (7819), 115-119 (2020); 2020.",10.1038/s41586-020-2380-z,"Chain H, antibody heavy chain","Chain L, antibody light chain",2022-03-15
680,CB6,CB6,7C01_C,7C01_D,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhh,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2; Nature 584 (7819), 120-124 (2020); 2020.",10.1038/s41586-020-2381-y,"Chain C, CB6 heavy chain","Chain D, CB6 light chain",2022-03-15
682,S309,S309,6WPT_D,6WPT_E,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.",10.1101/2020.04.07.023903,"Chain D, S309 neutralizing antibody heavy chain","Chain E, S309 neutralizing antibody light chain",2022-03-15
687,S309,S309,6WS6_E,6WS6_F,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.",10.1101/2020.04.07.023903,"Chain E, S309 antigen-binding (Fab) fragment, heavy chain","Chain F, S309 antigen-binding (Fab) fragment, light chain",2022-03-15
690,B38,B38,7BZ5_H,7BZ5_L,SARS-CoV-2,Homo sapiens (human),gdevqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycareaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,gddivmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,Y. et al.; A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2; Science 368 (6496), 1274-1278 (2020); 2020.",10.1126/science.abc2241,"Chain H, Heavy chain of B38","Chain L, Light chain of B38",2022-03-15
691,CR3022,CR3022,6W41_H,6W41_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV; Science 368 (6491), 630-633 (2020); 2020.",10.1126/science.abb7269,"Chain H, CR3022 Fab heavy chain","Chain L, CR3022 Fab light chain",2022-03-15
692,7D10,7D10,6J11_F,6J11_G,MERS-CoV,Mus musculus (house mouse),gggsgggsgggsevqlvesgaevvkpgasvkmsckasgypftsynihwikqtpgqglewigaiypgngdtsytqkfkvkatltsdkssstaymqlssltsedsavyfcarygnypsyamdywgqgtsvtvss,divmtqspasltvslgqratiscrasksvsasgynylhwyqqrpgqppklliylafnlesgvparfngsgsgtdftlnihpveeedaatyycqhsrdlpftfgsgtkleik,"Zhou,H. et al.; Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein; Nat Commun 10 (1), 3068 (2019); 2019.",10.1038/s41467-019-10897-4,"Chain F, VH of 7D10","Chain G, VL of 7D10",2022-03-15
695,LCA60,LCA60,6NB4_H,6NB4_L,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvss,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvt,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain H, LCA60 heavy chain","Chain L, LCA60 light chain",2022-03-15
698,S230,S230,6NB7_H,6NB7_L,SARS-CoV,Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavss,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain H, S230 heavy chain","Chain L, S230 light chain",2022-03-15
703,S230,S230,6NB8_H,6NB8_L,SARS-CoV,Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain H, S230 antigen-binding (Fab) fragment, heavy chain","Chain L, S230 antigen-binding (Fab) fragment, light chain",2022-03-15
704,LCA60,LCA60,6NB5_I,6NB5_M,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvtgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.",10.1016/j.cell.2018.12.028,"Chain I, LCA60 antigen-binding (Fab) fragment, heavy chain","Chain M, LCA60 antigen-binding (Fab) fragment, light chain",2022-03-15
706,CDC2-C2,CDC2-C2,6C6Z_H,6C6Z_L,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycaregghqgycsggscydfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkglevlfq,dvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpafgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J. Virol. 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,"Chain H, Antibody CDC2-C2 heavy chain","Chain L, Antibody CDC2-C2 light chain",2022-03-15
708,JC57-14,JC57-14,6C6Y_H,6C6Y_L,SARS-CoV,Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveia,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,"Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",2022-03-15
710,JC57-14,JC57-14,6C6X_H,6C6X_L,SARS-CoV,Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggsk,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.",10.1128/JVI.02002-17,"Chain H, JC57-14 Heavy chain","Chain L, JC57-14 Light chain",2022-03-15
714,MCA1,MCA1,5GMQ_B,5GMQ_C,SARS-CoV,Homo sapiens (human),atrleesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaskqgdyydrtsyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkts,dveltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chen,Z. et al.; Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset; J. Infect. Dis. 215 (12), 1807-1815 (2017); 2017.",10.1093/infdis/jix209,"Chain B, MCA1 heavy chain","Chain C, MCA1 light chain",2022-03-15
715,4C2,4C2,5DO2_C,5DO2_D,MERS-CoV,Mus musculus (house mouse),dvklvesggglvkpggslklscaasgftfssytmswvrqtpekrlewvatissggsytyypdsvkgrftisrdnakntlylqmsslksedtamyyctrdgndydywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,diqmtqttsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlprtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Li,Y. et al.; A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein; Cell Res. 25 (11), 1237-1249 (2015); 2015.",10.1038/cr.2015.113,"Chain C, 4C2 heavy chain","Chain D, 4C2 light chain",2022-03-15
717,H11B11-FAB,H11B11-FAB,7E7E_C,7E7E_D,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveshhhhhhhh,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Du,Y. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Nat Commun 12 (1), 5000 (2021); 2021.",10.1038/s41467-021-25331-x,"Chain C, h11B11-Fab","Chain D, h11B11-Fab",2022-03-15
719,8D3,8D3,7W9F_A,7W9F_B,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.",10.1038/s41467-022-28528-w,"Chain A, The heavy chain of 8D3","Chain B, The light chain of 8D3",2022-03-15
720,S-E6,S-E6,7KN4_M,7KN4_N,SARS-CoV-2,Homo sapiens (human),qvtlresgpglvkpsetlsltcavsggslssvnyywswirqhpgkglewigyiyysgstnynpslksrvtmsldtsknqfslklssvtaadtavyycatpgaimgalhiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qavltqpssasstpgqrviiscsgsssnigsntvswyqqvpgaapklliyfdyrrpsgvpdrfsgtrsgtsaslgisglqsedeadyycaawddslsawvfgrgtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.",10.1002/advs.202102181,"Chain M, S-E6 Fab heavy chain","Chain N, S-E6 Fab light chain",2022-03-15
722,S-B8,S-B8,7KN3_M,7KN3_N,SARS-CoV-2,Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgftvslshmnwvrqapgkglewvsitygdgnsdyadsvkgrftisrdnskntlylqmnslraedtavyycareyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.",10.1002/advs.202102181,"Chain M, S-B8 Fab heavy chain","Chain N, S-B8 Fab light chain",2022-03-15
724,RBD-CHAB15,RBD-CHAB15,7EH5_E,7EH5_Q,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqleesgpglvqpsqslsitctvsdfslttygvhwvrqspgkglewlgviwsggstdynaafisrlsiskdnsksqvffkmnslqtndtaiyycarmgdgyyvgamdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,diqltqspailsvspgervsfscrasqsigtsihwyqqrtngsprhlikyasesisgipsrfsgsgsgtdftltingvesediadyycqqghnwpltfgagtklelkratvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function; Nat Struct Mol Biol 28 (9), 731-739 (2021); 2021.",10.1038/s41594-021-00652-z,"Chain E, RBD-chAb15, heavy chain","Chain Q, RBD-chAb15, light chain",2022-03-15
730,F26G19,F26G19,3BGF_B,3BGF_C,SARS-CoV,Mus musculus (house mouse),evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Pak,J.E. et al.; Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain; J. Mol. Biol. 388 (4), 815-823 (2009); 2008.",10.1016/j.jmb.2009.03.042,"Chain B, F26G19 Fab","Chain C, F26G19 Fab",2022-03-15
732,DH851.3,DH851.3,7LU9_q,7LU9_r,not determined,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgg,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaec,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",NaN,"Chain q, DH851.3 heavy chain","Chain r, DH851.3 light chain",2022-03-15
733,DH851.3,DH851.3,7LU9_p,7LU9_o,not determined,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvap,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",NaN,"Chain p, DH851.3 heavy chain","Chain o, DH851.3 light chain",2022-03-15
738,DH898.1,DH898.1,7LUA_i,7LUA_j,not determined,Homo sapiens (human),qdlllqsgaevrepgasvtvscqasnytfpdyyihwvrlvpgqglewlgemkpkvgvtnvskkirdrlfmtadtstdtaymvlsaltpgdtaiyyctrlepdflsgwahwgkgvlvtvspastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,eivmtqtplslsvtpgepaslscrssasllhgngntylhwylrkagqspqllifggskrvpgisdrfigsgagtnftlkissveaddvgfyycaqgvafpwtfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgvlktgnsqesvteqdskdntyslsstltlsntdyqshnvyacevthqglsspvtksfnrge,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.",NaN,"Chain i, DH898.1 heavy chain","Chain j, DH898.1 light chain",2022-03-15
742,DH717.1,DH717.1,6XRJ_H,6XRJ_L,not determined,Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsgvsindgydwtwirqtpgkglewigyvfgrsgnfnlnpslrnrgiiskdtcknqfslnlnsataadtavyfcargmeglfaaynsldvwgrgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveikt,altqppsvsgspgqsviisctgtssdigqynsvswyqqhpdkapklviygvtsrpsgvsdrfsgskygdtasltisglqaedeadyycsshadenmalfgggtrltvlgqpkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapa,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2020.",NaN,"Chain H, DH717.1 heavy chain Fab fragment","Chain L, DH717.1 light chain Fab fragment",2022-03-15
746,CR3022,CR3022,7JN5_H,7JN5_L,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvvsrrlppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,N.C. et al.; A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody; PLoS Pathog 16 (12), e1009089 (2020); 2020.",10.1371/journal.ppat.1009089,"Chain H, CR3022 heavy chain","Chain L, CR3022 light chain",2022-03-15
747,NaN,NaN,QXP08760,QXP08759,SARS-CoV-2,synthetic construct,evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapefeggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Unpublished; 2021.",NaN,"humanized ACE2-targeting immunoglobulin heavy chain, partial [synthetic construct]","humanized ACE2-targeting immunoglobulin light chain, partial [synthetic construct]",2022-03-15
748,NaN,NaN,7O7F_H,7O7F_F,not determined,Mus musculus (house mouse),dvqlvesggglvqpggsrklscsasgfafssfgmhwvrqapekglewvayissgsgtiyyadtvkgrftisrddpkntlflqmtslrsedtamyycvrsiyyygsspfdfwgqgttltvssakttppsvyplapgcgdttgssvtlgclvkgyfpesvtvtwnsgslsssvhtfpallqsglytmsssvtvpsstwpsqtvtcsvahpassttvdkkleps,divmtqatssvpvtpgesvsiscrssksllhsngntylywflqrpgqspqlliyrmsnlasgvpdrfsgsgsgtaftltisrleaedvgvyycmqhleypltfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Isaikina,P. et al.; Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist; Sci Adv 7 (25) (2021); 2021.",10.1126/sciadv.abg8685,"Chain H, Fab antibody fragment heavy chain","Chain F, Fab antibody fragment light chain",2022-03-15
749,NaN,NaN,QVL61760,QVL61759,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]","anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15
750,1C4,1C4,6XGC_I,6XGC_J,not determined,Macaca fascicularis (crab-eating macaque),evqlvesggglakpggslrlscaasgftfstyamhwvrqapgkglewisginsgggstwytasvkgrftisrdnskstlslqmnslrtedtavyycakdggnaifglvitnygldswgqgavvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppthhhhhh,qsvltqppsasgapgqsvtiscsgsssnfgsnhvywyqqlsgkapklliynnnrrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwdsslnnvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgvvkvawkadgnsvntgvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaecs,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.",10.1126/scitranslmed.abe5449,"Chain I, 1C4 Fab heavy chain","Chain J, 1C4 Fab light chain",2022-03-15
753,D12,D12,4ZPV_A,4ZPV_B,MERS-CoV,Mus musculus (house mouse),evklvesggglvkpggslklscaasgftfssyamswvrqtpekrlewvatissggtytyypdsvkgrftisrdnaentlylqmsslrsedtamyycvrdgnsmdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiepr,diqmtqttsslsaslgdrvtiicrasqdinnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgsdysltisnleqediatyfcqqantlpptfgagtklelrradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,L. et al.; Evaluation of candidate vaccine approaches for MERS-CoV; Nat Commun 6, 7712 (2015); 2015.",10.1038/ncomms8712,"Chain A, D12 Fab Heavy chain","Chain B, D12 Fab light chain",2022-03-15
757,M336,M336,4XAK_D,4XAK_E,MERS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtasyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstscnrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ying,T. et al.; Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody; Nat Commun 6, 8223 (2015); 2015.",10.1038/ncomms9223,"Chain D, Heavy chain of neutralizing antibody m336","Chain E, Light chain of neutralizing antibody m336",2022-03-15
759,1AF10,1AF10,4F2M_C,4F2M_D,SARS-CoV,Mus musculus (house mouse),qvqlqqsgpelvkpgasvkisckasgyafssswmnwvkqrpgqglewigriypgdgetnysekfkgkatltadkssstaymhlssltsvdsavyfcarggyrydpyyamdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilltqspailsvspgervslscrasqsigtsihwyqqrtngsprplikyasesisgipsrfsgsgsgtdftlninsvesediadyfcqqtdswpttfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Reguera,J. et al.; Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies; PLoS Pathog. 8 (8), E1002859 (2012); 2012.",10.1371/journal.ppat.1002859,"Chain C, monoclonal antibody 1AF10, heavy chain","Chain D, monoclonal antibody 1AF10, light chain",2022-03-15
761,S/RBD,S/RBD,QOQ45101,QOQ45102,"SARS-CoV-2, Spike protein RBD",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,W. et al.; Phage display library derived human Fab against SARS-CoV-2 spike protein receptor binding domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 S/RBD immunoglobulin heavy chain, partial [synthetic construct]","anti-SARS-CoV-2 S/RBD immunoglobulin light chain, partial [synthetic construct]",2022-03-15
762,NaN,NaN,AAC53258,AAC53259,SARS-CoV,Mus musculus (house mouse),mkcswvifflmavviginsevqlqqsgaelvrsgasvklsctasgfnikdyymhwvkqrpeqglewigwidpengyteyapkfqgkatvtadtssntaylqlssltsedtavyycnafyyrydafdywgqgttltvss,mesqiqvfvfvflwlsgvdgdivmtqshkfmstsvgdrvsitckasqdvstavawyqqkpgqspklliysasyrytgvpvrftgsgsgtdftftissvqaedlavyycqqhystpytfgggtkleik,"Castilla,J. et al.; Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies; J. Virol. 71 (7), 5251-5258 (1997); 1997.",NaN,"monoclonal antibody gamma one chain variable region, partial [Mus musculus]","monoclonal antibody kappa chain variable region, partial [Mus musculus]",2022-03-15
763,NaN,NaN,ABA54613,ABA54614,SARS-CoV,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtv,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"ter Meulen,J. et al.; Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants; PLoS Med. 3 (7), E237 (2006); 2006.",10.1371/journal.pmed.0030237,"anti-SARS-CoV immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS-CoV immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15
764,NaN,NaN,AAS19425,AAS19432,SARS-CoV,Homo sapiens (human),evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,ttltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"anti-SARS S protein immunoglobulin heavy chain variable region, partial [Homo sapiens]","anti-SARS S protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15
765,ANTI-HUMAN,ANTI-HUMAN,AJD85779,AJD85780,not determined,synthetic construct,mgwslillflvavatrvhsevqlvesggglvqpggslklscatsgftfsdyymywvrqapgkglewvayinsgggstyypdtvkgrftisrdnakntlylqmnslraedtavyycarrglpfhamdywgqgtlvtvssaktkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapefeggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgkasqtptntisvtptnnstptnnsnpkpnpasekirlrpggkkkyklkhivasssvspttsvhptptsvpptptksspasnppipvgeiykrwiilglnkivrmysptsildasptstpadsstitptatptatptikgashtqgyfpdwqnytpgpgvrypltfgwlyklastvtptatatpsaivttitptattkpas,mrvpaqllgllllwlpgarcdiqmtqspsslsasvgdrvtitcsasqgisnylnwyqqkpgkavklliyytsilhsgvpsrfsgsgsgtdytltisslqpedfatyycqqfnklpptfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecasaifqssmtkilepfrkqnpdiviyqymddlyastvtptatatpsaivttitptattkpasvgfpvtpqvplrpmtykaavdlshflkekgglas,"Flamar,A.L. et al.; Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells; AIDS 27 (13), 2041-2051 (2013); 2015.",10.1097/QAD.0b013e3283624305,anti-human CD40 12E12 antibody HIV antigen fusion protein [synthetic construct],anti-human CD40 12E12 antibody HIV antigen fusion protein [synthetic construct],2022-03-15
766,NaN,812L,7EZV_H,7EZV_L,SARS-CoV-2,Homo sapiens (human),mgwslillflvavatrvlsevqlvqsgaevkkpgeslkiscqfseyklisfwiawvrqrpgkglewmgiiypddsdtkyspssqgqvtisadksirtaylqwsslmasdtamyyctsgsyygtldfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,mgwsciilflvatatgvhsdieitqspsslsasvgdrvtiscrasqdirtyvawyqqrpgkvprlliyaastlqsgvpsrfsgrgsgtdftltisslqpedvatyycqqynsapltfgggakveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.",10.1038/s41422-021-00555-0,"Chain H, H","Chain L, 812L",2022-03-15
767,GAMMA-1,NaN,7NP1_K,7NP1_O,SARS-CoV-2,Homo sapiens (human),evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,asdiqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,"Chain K, Immunoglobulin gamma-1 heavy chain","Chain O, Immunoblobulin light chain",2022-03-15
771,NaN,NaN,7BNV_H,7BNV_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhpspyyygsgsysggfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,asdivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqydnwplmhtfgqgtkleikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,"Chain H, Heavy Chain","Chain L, Light Chain",2022-03-15
772,NaN,NaN,7PHG_H,7PHG_L,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvss,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.",10.1016/j.celrep.2021.109814,"Chain H, Heavy ChaIn variable","Chain L, Light ChaIn",2022-03-15
773,NaN,NaN,7RR0_B,7RR0_C,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgnanyaprfqervtitrdmstntaymelsslrsedtavyycaapncsrtlcydgfnmwgqgtmvtv,eivltqspgslslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyycqqydsspwtfgqgtkvei,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain B, PDI 222 Fab Heavy Chain","Chain C, PDI 222 Fab Light Chain",2022-03-15
774,NaN,NaN,7MZN_H,7MZN_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscvasgltvssnymnwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslraedtavyycarvggycssancvsdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapkimiydasiletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtqleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 231 heavy chain","Chain L, PDI 231 light chain",2022-03-15
775,NaN,NaN,7MZM_H,7MZM_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkgpewvsyisggssftnyadsvqgrftiyrdnaknsmflrmnslraedtavyycarspptgdssdwydspaynnyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspvtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsptvtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 215 heavy chain","Chain L, PDI 215 light chain",2022-03-15
776,NaN,NaN,7MZL_H,7MZL_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlqqwgagllkpsetlsltcvvygetlsgyywtwirqspgkglewigeislrgtanynpslksrvtlsveasknqfslkmtsvtaadtavyycvggvvldnvvwfdpwgqgipvtvslastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,esvltqspvslslspgeratlscrasqsvgtylawyqhrpgqaprlliynaskratgiparfsgsgsgtdftltisslepedlavyfcqqrsnwltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 210 heavy chain","Chain L, PDI 210 light chain",2022-03-15
777,NaN,NaN,7MZK_H,7MZK_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),lvqlvqsgaevkkpgasvkisckasgytftsyymhwvrqapgqglewmgiinpsgggtsyaqkfqgrvtmtrdtststvymeltslrsddtavyycakdrvtifwgngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,divmtqspvslavslgeratikckssqsvlyssnnknylgwyqqkpgqplrlliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqysttpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 96 heavy chain","Chain L, PDI 96 light chain",2022-03-15
779,NaN,NaN,7MZK_F,7MZK_D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain F, WCSL 129 heavy chain","Chain D, WCSL 129 light chain",2022-03-15
781,NaN,NaN,7MZJ_N,7MZJ_M,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vvqlvesggglvkpggslrlscaasgftfsyawmswvrqapgkglewvgrikrksdggttdyaapvkgrftisrddskntlylqmsslktedtavyycttdlcrstscehdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtvtcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpaitfgqgtrvqikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain N, PDI 93 heavy chain","Chain M, PDI 93 light chain",2022-03-15
786,NaN,NaN,7MZH_B,7MZH_C,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarsyydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsvltqppsvseaprqrvtiscsgsssnighnavhwyqqlpgkapklliyyddllpagvsdrfsgsksgtsaslaisglqsedeadyycaawddilngpvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain B, WCSL 119 heavy chain","Chain C, WCSL 119 light chain",2022-03-15
788,NaN,NaN,7MZG_H,7MZG_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsvfypggstynadsvkgrftisrdnskntlylqmnslraedtavyycardavyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqesystpglftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 42 heavy chain","Chain L, PDI 42 light chain",2022-03-15
789,NaN,NaN,7MZF_H,7MZF_L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggttyyadsvkgrftisrdsskntlylqmnslraedtavyycardrgdylfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqppsplfasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgseteftltisslqpddfatyycqqynsyfptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 37 heavy chain","Chain L, PDI 37 light chain",2022-03-15
790,NaN,NaN,7E8F_D,7E8F_E,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain D, H","Chain E, L",2022-03-15
791,NaN,NaN,7E8C_O,7E8C_Q,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdkskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscd,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.",10.1038/s41422-021-00514-9,"Chain O, H","Chain Q, L",2022-03-15
794,NaN,NaN,7DZY_O,7DZY_P,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkveinrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.",10.1016/j.cell.2021.05.032,"Chain O, Fab Heavy chain of enhancing antibody 2490","Chain P, Fab light chain of enhancing antibody 2490",2022-03-15
797,NaN,NaN,7DZX_H,7DZX_L,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvaninqdgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycardwdydiltgswfgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Liu,Y. et al.; An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies; Cell 184 (13), 3452-3466 (2021); 2021.",10.1016/j.cell.2021.05.032,"Chain H, Fab Heavy chain of enhancing antibody","Chain L, Fab light chain of enhancing antibody",2022-03-15
798,NaN,NaN,7KLG_I,7KLG_M,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqsyrypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.",10.1101/2020.10.31.362848,"Chain I, Fab 15033 heavy chain","Chain M, Fab 15033 light chain",2022-03-15
800,C1A-B12,C1A-B3,7KFV_H,7KFV_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggatyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlisypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, Heavy chain of antibody C1A-B12 Fab","Chain L, light chain of antibody C1A-B3 Fab",2022-03-15
803,NaN,NaN,7K9Z_B,7K9Z_A,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasggtfstygiswvrqapgqglewmgwispnsggtdlaqkfqgrvtmtrdtststvymelsslrsedtavyycasdprddiaggywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.",NaN,"Chain B, Fab Heavy Chain","Chain A, Fab Light Chain",2022-03-15
804,NaN,NaN,7K9Z_H,7K9Z_L,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,sdiqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.",NaN,"Chain H, Fab Heavy Chain","Chain L, Fab Light Chain",2022-03-15
805,NaN,NaN,5ZXV_C,5ZXV_D,MERS-CoV,Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyycagndywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,svltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,"Chain C, heavy chain","Chain D, light chain",2022-03-15
807,NaN,NaN,5YY5_C,5YY5_D,MERS-CoV,Homo sapiens (human),gvqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvt,ltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqlt,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,"Chain C, Heavy chain","Chain D, Light chain",2022-03-15
808,NaN,NaN,5YY5_H,5YY5_L,MERS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfsnyamywvrqapgkglewvalisydistdyyadsvkgrftisrdnskntiylqmnnlrtedtalyyctntyywgqgtlvtvs,gsqpvltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvl,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,"Chain H, Heavy chain","Chain L, Light chain",2022-03-15
809,4-61CHAIN,C2312_LIGHT_IGLV2-14_IGLJ2IGL@,7D03_H,7D03_L,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsvssgsyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarercyygsgraprcvwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain H, Immunoglobulin heavy variable 4-61,chain H of FabP5A-2G7,Epididymis luminal protein 214","Chain L, IGL c2312_light_IGLV2-14_IGLJ2,IGL@ protein",2022-03-15
810,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,C4203_LIGHT_IGKV1-9_IGKJ4UNCHARACTERIZED,7D00_J,7D00_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,chain H of FabP5A-1B8,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-15
812,1-8IMMUNOGLOBULIN,C168_LIGHT_IGKV4-1_IGKJ4IMMUNOGLOBULIN,7CZZ_J,7CZZ_N,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycaryivvvpaakgfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214","Chain N, IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant",2022-03-15
817,4-59CHAIN,C168_LIGHT_IGKV4-1_IGKJ4UNCHARACTERIZED,7CZX_J,7CZX_N,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyisysgstnynpslksrvtisldtsknqfslklssvtaadtavyycasngqyydiltgqppdywyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 4-59,chain H of P5A-1B9,IGH@ protein","Chain N, IG c168_light_IGKV4-1_IGKJ4,Uncharacterized protein",2022-03-15
822,3-30-3CHAIN,1-33UNCHARACTERIZED,7CZV_J,7CZV_N,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 3-30-3,chain H of P5A-1B6_3B,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-15
825,3-30-3IMMUNOGLOBULIN,1-33IMMUNOGLOBULIN,7CZU_H,7CZU_K,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain H, Immunoglobulin heavy variable 3-30-3,Immunoglobulin heavy variable 3-30-3,Chain H of P5A-1B6_2B,Immunoglobulin gamma-1 heavy chain,Immunoglobulin gamma-1 heavy chain","Chain K, Immunoglobulin kappa variable 1-33,Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-15
827,3-33CHAINH,C689_LIGHT_IGLV5-37_IGLJ3IGL@,7CZT_I,7CZT_M,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarwfhtggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qpvltqppsssaspgesarltctlpsdinvssyniywyqqkpgsppryllyyysdsdkgqgsgvpsrfsgskdasantgillisglqsedeadyycmiwpsnalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain I, Immunoglobulin heavy variable 3-33,chainH of P5A-2G9,Immunoglobulin gamma-1 heavy chain","Chain M, IG c689_light_IGLV5-37_IGLJ3,IGL@ protein",2022-03-15
829,C542_HEAVY_IGHV3-53_IGHD3-10_IGHJ6IGH@,C4203_LIGHT_IGKV1-9_IGKJ4UNCHARACTERIZED,7CZS_J,7CZS_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-15
832,C542_HEAVY_IGHV3-53_IGHD3-10_IGHJ6IGH@,C4203_LIGHT_IGKV1-9_IGKJ4IGL,7CZR_J,7CZR_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein","Chain N, IGL c4203_light_IGKV1-9_IGKJ4,IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-15
834,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,1-33UNCHARACTERIZED,7CZQ_J,7CZQ_N,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaregpksitgtafdiwgqgtivtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnyfnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,Chain H of P2B-1A10,Immunoglobulin gamma-1 heavy chain","Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-15
836,4-59CHAIN,C181_LIGHT_IGLV2-14_IGLJ3IGL@,7CZP_J,7CZP_N,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtskkqfslklssvtaadtavyycarlerdwpldafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapkfmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsnntfafgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.",10.1038/s41422-021-00487-9,"Chain J, Immunoglobulin heavy variable 4-59,Chain H of P2B-1A1,Anti-RhD monoclonal T125 gamma1 heavy chain","Chain N, IG c181_light_IGLV2-14_IGLJ3,IGL@ protein",2022-03-15
838,BD-629,IGK@,7CH5_H,7CHC_L,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-629 Fab H","Chain L, IGK@ protein",2022-03-15
839,NaN,NaN,6YOR_B,6YOR_C,"SARS-CoV-2, Spike protein",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.",10.1016/j.chom.2020.06.010,"Chain B, IgG H chain","Chain C, IgG L chain",2022-03-15
841,ANTI-H5N1,8D3,7W9E_D,7W9E_E,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun 13 (1), 871 (2022); 2022.",10.1038/s41467-022-28528-w,"Chain D, Anti-H5N1 hemagglutinin monoclonal anitbody H5M9 heavy chain","Chain E, The light chain of 8D3 fab",2022-03-15
842,NaN,NaN,2DD8_H,2DD8_L,SARS-CoV,Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,"Chain H, IGG Heavy Chain","Chain L, IGG Light Chain",2022-03-15
845,NaN,NaN,6WZT_G,6WZT_F,not determined,Macaca fascicularis (crab-eating macaque),qvqlqesgpglvkpsetlsltcavsggtfsayywgwirqppgkglewigsisggsgstdyspslksratisrdtsknqfslkltsvtaadtavyycvrkywgdyyanwfdvwgpgvlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppt,diqmtqspsslsasvgdtvtitcrasqsisswlawyqqkpgkapklliykasslqggvpsrfsgsgsgsdftltisslqsedfatyycqqysgrpptfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlsstdyqshnvyacevthqglsspvtksfnrgec,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.",10.1126/scitranslmed.abe5449,"Chain G, Cyno antibody heavy chain","Chain F, Cyno antibody light chain",2022-03-15
848,53181-1,5317-10,MZ517191,MZ517250,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyvltwvrqapgqglewmgwisayngstnyaqnlqgrvtmttdtststaymelrslrsddtavyycardpasyydfwsgyvdyyyygmdvwgqgttvtvss,divmtqsplslpvtpgepasiscrssqsllfgngytylnwylqkpgqspqlliylgsnrasgvpdrfsvsgsgtdftliisrveaedvgvyfcmqalqtpwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"Homo sapiens isolate 53181-1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 5317-10 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
849,5885-1,5885-13,OM001674,OM001699,SARS-CoV-2,Homo sapiens (human),qvqlqesgpgvvkpsetlsltcsvsggsisstnyywawirqppgkglewigsifytgstyynpslksrviisvdtsknqfslrltsvtaadtavyycarytsyydrsgfrrveyfqhwgqgtlvtvss,syeltqppsvsvspgqtatitcsgdklgdkyacwfqqkpgqspvlviyhdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsstavfgtgtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"Homo sapiens isolate 5885-1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 5885-13 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
850,CS1,CS99,OM457661,OM457822,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfqyvaathspyyyygmdvwgqgttvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgegtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"Homo sapiens clone CS1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone CS99 anti-SARS-CoV-2 immunoglobulin kappa chain variable region mRNA, partial cds",2022-03-15
851,A10,A10,MZ927186,MZ927185,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgygdyrglygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasrdinkylawyqqkpgkapklliygessraagvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone A10 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone A10 immunoglobulin light chain variable region gene, partial cds",2022-03-15
852,A11,A11,MZ927188,MZ927187,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysygylsgmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone A11 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone A11 immunoglobulin light chain variable region gene, partial cds",2022-03-15
853,A12,A12,MZ927190,MZ927189,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgwgsllngiavagldywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone A12 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone A12 immunoglobulin light chain variable region gene, partial cds",2022-03-15
854,B2,B2,MZ927192,MZ927191,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardaysgsypyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasegisnylawyqqkpgkapklliygtsdrasgipsrfsgsgsgtdftltisslqpedfanyycqqysafpwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone B2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B2 immunoglobulin light chain variable region gene, partial cds",2022-03-15
855,B3,B3,MZ927194,MZ927193,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgytspatihwvrqapgkglewmggispykgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycakdsyyydssgsglgggfdywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone B3 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B3 immunoglobulin light chain variable region gene, partial cds",2022-03-15
856,B7,B7,MZ927196,MZ927195,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycakdgwgsllngiavagldywgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone B7 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B7 immunoglobulin light chain variable region gene, partial cds",2022-03-15
857,B11,B11,MZ927198,MZ927197,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardaypyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone B11 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone B11 immunoglobulin light chain variable region gene, partial cds",2022-03-15
858,C1,C1,MZ927200,MZ927199,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmggistqrgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgyygsgtyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqsigsflawyqqkpgkapklliygesnratgvpsrfsgsgsgtdftltisslqpedfanyycqqynrypwafgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone C1 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C1 immunoglobulin light chain variable region gene, partial cds",2022-03-15
859,C2,C2,MZ927202,MZ927201,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytspatihwvrqapgkglewmggispykgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardaysssyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasediskylawyqqkpgkapklliygasnlhtgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone C2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C2 immunoglobulin light chain variable region gene, partial cds",2022-03-15
860,C4,C4,MZ927204,MZ927203,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysgydygsvgrdyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone C4 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C4 immunoglobulin light chain variable region gene, partial cds",2022-03-15
861,C7,C7,MZ927206,MZ927205,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysftnyaihwvrqapgkglewmggitpynadtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardggnwaapysmdvwgngtlvtvss,diqmtqspssvsasvgdrvtitcrashgissylawyqqkpgkapklliydatiratgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone C7 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone C7 immunoglobulin light chain variable region gene, partial cds",2022-03-15
862,D2,D2,MZ927208,MZ927207,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardarlldywgqgaqvtvss,diqmtqspssvsasvgdrvtitcrasrsignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone D2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone D2 immunoglobulin light chain variable region gene, partial cds",2022-03-15
863,D3,D3,MZ927210,MZ927209,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgysfadyaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgydfwsgsygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyycqqyseypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone D3 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone D3 immunoglobulin light chain variable region gene, partial cds",2022-03-15
864,F1,F1,MZ927212,MZ927211,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgypftsyaihwvrqapgkglewmggitpynadtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgyssgyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone F1 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone F1 immunoglobulin light chain variable region gene, partial cds",2022-03-15
865,F5,F5,MZ927214,MZ927213,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgytfsnhaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysgyvegmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqnihsylawyqqkpgkapklliydtsklqsgvpsrfsgsgsgtdftltisslqpedfanyychqyaaypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone F5 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone F5 immunoglobulin light chain variable region gene, partial cds",2022-03-15
866,F7,F7,MZ927216,MZ927215,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysfstytihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysgyessyyyygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone F7 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone F7 immunoglobulin light chain variable region gene, partial cds",2022-03-15
867,G2,G2,MZ927218,MZ927217,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgytftanaihwvrqapgkglewmggigpgqgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardghcsggscpsgmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliygasiresgvpsrfsgsgsgtdftltisslqpedfanyycqqysafpwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone G2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G2 immunoglobulin light chain variable region gene, partial cds",2022-03-15
868,G4,G4,MZ927220,MZ927219,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgytlsdhaihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgydfwsgsygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone G4 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G4 immunoglobulin light chain variable region gene, partial cds",2022-03-15
869,G5,G5,MZ927222,MZ927221,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgysftdhsihwvrqapgkglewmgginpytgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgysygylsgmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdishhlawyqqkpgkapklliydaslratgipsrfsgsgsgtdftltisslqpedfanyychqyaaypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone G5 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G5 immunoglobulin light chain variable region gene, partial cds",2022-03-15
870,G6,G6,MZ927224,MZ927223,SARS-CoV-2,synthetic construct,evqlvesgaevkkpgasvkvsckvsgytfsnhaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgypgdysgldvwgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqpissylawyqqkpgkapklliyeasklqsgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone G6 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G6 immunoglobulin light chain variable region gene, partial cds",2022-03-15
871,G12,G12,MZ927226,MZ927225,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgytfsnhaihwvrqapgkglewmgginpnigdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgygdyrglygmdvwgqgttvtvss,diqmtqspssvsasvgdrvtitcrasqdignhlawyqqkpgkapklliyassnlasgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone G12 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone G12 immunoglobulin light chain variable region gene, partial cds",2022-03-15
872,H2,H2,MZ927228,MZ927227,SARS-CoV-2,synthetic construct,evqlvqsgaevkkpgasvkvsckvsgypftrstihwvrqapgkglewmgginagtgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycardgyssgyygmdvwgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqgisdflawyqqkpgkapklliygasnratgvpsrfsgsgsgtdftltisslqpedfanyychqyatypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone H2 immunoglobulin heavy chain variable region gene, partial cds","Synthetic construct clone H2 immunoglobulin light chain variable region gene, partial cds",2022-03-15
873,C1C-A3,C1C-A3,OL621229,OL621230,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvss,eivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleik,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor-binding domain; Science (2022) In press; 2021.",NaN,"Homo sapiens clone C1C-A3 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone C1C-A3 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
875,WRAIR-2004,WRAIR-2196,MZ825529,MZ825470,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpssggtnyaqkfqgrvtmtrdtsistaymelsslrsddtavyycatdgddgenwfdpwgqgtlvivss,qpvltqpssvsvspgqtatitcsgdvlakkyarwfqqkpgqapmlviykdterpsgiperfsgsssgttvtltingaqvedeadyycysaaawvfgggtkltvlg,"Krebs,S.J. et al.; Direct Submission; Submitted (16-AUG-2021) MHRP, HJF/WRAIR, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA; 2021.",NaN,"Homo sapiens isolate WRAIR-2004 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate WRAIR-2196 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
876,AB007_VH,AB200_VL,OK094317,OK094392,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasphcsstsclyhyyyygmdvwgqgttvtvss,qseltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsayvvfgggtkltvl,"Altomare,C.G. et al.; Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses; Unpublished; 2021.",NaN,"Homo sapiens isolate ab007_VH immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate ab200_VL immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
877,12C10,12C10,MZ751047,MZ751048,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evklqesggglvkpggslklscaasgftfsnysmswvrqtpekrlewvatisngggyiyyldsvkgrftisrdnakntlylqmsslrsedtamyycgrprpekefiststamdhwgqgttvt,evtmsckssqsllyssyqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypftfgsgtkleik,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",NaN,"Mus musculus clone 12C10 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus clone 12C10 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
878,CB6,CB6,MT470197,MT470196,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk*,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs*,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,"Homo sapiens clone CB6 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone CB6 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
879,XG81,XG81,MZ668598,MZ668599,not determined,Homo sapiens (human),mefglswiflaailkgvqcevqlvesggglvkpggslrlscaasgfsfsdawmswvrqapgkglewvgrikskvdggttdyaapvkgrftisrdeskdilylqmnslktedtavyfcatavvvvvtnglddafdiwgqgtmvtvss,mrvpaqllgllllwlrgarcdiqmtqspsslsasvgdrvtitcrasqsissslnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsfstlftfgpgtkvdlk,"Xie,J. et al.; Direct Submission; Submitted (26-JUL-2021) The First Affiliated Hospital of USTC, University of Science and Technology of China, Lujiang Road 17, Hefei, Anhui 230001, China; 2021.",NaN,"Homo sapiens isolate XG81 immunoglobulin heavy chain variable region gene, partial cds","Homo sapiens isolate XG81 immunoglobulin light chain variable region gene, partial cds",2022-03-15
880,XG83,XG83,MZ668600,MZ668601,not determined,Homo sapiens (human),mdwtwrflfvvaaatgvqsqvqlvqsgaevkkpgssvkvsckasgdtfssytitwvrqapgqglewmgrvipilgtanyaqkfqgrvtitadkstrtaymelsslrsddsamyycarergysgngaayyfdywgqgtlvtvss,mawspllltllahctgswaqsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygdsnrpsgvpdrfsgsksgtsaslaitglqaedeadfycqsydsslstsifgggtkltvl,"Xie,J. et al.; Direct Submission; Submitted (26-JUL-2021) The First Affiliated Hospital of USTC, University of Science and Technology of China, Lujiang Road 17, Hefei, Anhui 230001, China; 2021.",NaN,"Homo sapiens isolate XG83 immunoglobulin heavy chain variable region gene, partial cds","Homo sapiens isolate XG83 immunoglobulin light chain variable region gene, partial cds",2022-03-15
881,CV503_VH,CV635_VL,MZ883076,MZ883093,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvss,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgtivtltisgvqaedeadyycqsadssatyvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"Homo sapiens clone CV503_VH immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone CV635_VL immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
882,H11B11,H11B11,MZ514138,MZ514137,SARS-CoV-2,synthetic construct,evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapefeggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Unpublished; 2021.",NaN,"Synthetic construct clone h11B11 humanized ACE2-targeting immunoglobulin heavy chain gene, partial cds","Synthetic construct clone h11B11 humanized ACE2-targeting immunoglobulin light chain gene, partial cds",2022-03-15
883,COV2-2072,COV2-2072,MT665419,MT665032,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"Homo sapiens isolate COV2-2072 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2072 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
884,COV2-2489,COV2-2489,MT665457,MT665070,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"Homo sapiens isolate COV2-2489 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2489 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
885,COV2-3012,COV2-3012,MT665458,MT665071,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"Homo sapiens isolate COV2-3012 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-3012 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
886,COV2-2183,COV2-2183,MT665805,MT665418,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"Homo sapiens isolate COV2-2183 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2183 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
887,COV2-2130,COV2-2130,MT665427,MT665040,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdvwmswvrqapgkglewvgrikskidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttagsyyydtvgpglpegkfdywgqgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkllmywastresgvpdrfsgsgsgaeftltisslqaedvaiyycqqyystltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"Homo sapiens isolate COV2-2130 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2130 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
888,COV2-2838,COV2-2838,MT665525,MT665138,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"Homo sapiens isolate COV2-2838 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2838 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
889,A19-46.1,A19-46.1,MZ458523,MZ458524,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftlssygmhwvrqapgkglewvavisydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycargwaywellpdyyygmdvwgqgttvtvss,qtvvtqepsfsvspggtvtltcglssgsvstayfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgrgivvfgggtkltvl,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"Homo sapiens isolate A19-46.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate A19-46.1 anti-SARS-CoV-2 immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15
890,A19-61.1,A19-61.1,MZ458525,MZ458526,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyafhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraddtavyycardlaiavagtwhyyngmdvwgqgttvtvss,diqmtqspssvsasvgdrviitcrasqgisswlawyqqkpgkapkvliydasslqsgvpsrfsgsgygtdftltisslqpedsatyycqqaksfpitfgqgtrleik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"Homo sapiens isolate A19-61.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate A19-61.1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
891,A23-58.1,A23-58.1,MZ458527,MZ458528,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"Homo sapiens isolate A23-58.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate A23-58.1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
892,B1-182.1,B1-182.1,MZ458529,MZ458530,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveir,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"Homo sapiens isolate B1-182.1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate B1-182.1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
893,CC40.5-HC,CC9.3-KLC,MW426536,MW426544,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewvavmsydgsvtyygdsvrgrftisrdnskntlylqmsslrtddtgvyycakgqplddiwglgtlvtvss,divmtqspdslavslgerasinckssqtisyisnnknylawyqqkpgqpprlliywastresgvpdrfsgggfgtdftltisslqaedvavyycqqyfntpwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"Homo sapiens isolate CC40.5-HC cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CC9.3-KLC cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
894,CC10.1-HC,CC40.7-LLC,MW532169,MW532198,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargksptvvtpwfdywgqgtlvtvss,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddgdrpsgiperfsgsnsgntatlaisrveagdeadyycqvwdssshwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"Homo sapiens isolate CC10.1-HC cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CC40.7-LLC cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
895,47D11,47D11,MW881223,MW881224,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsisshywswirqppgkglewigyiyysgstnhnpslksrvtisvdtsknqfslklssvtaadtavyycargvllwfgepifeiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastrapgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkveik,"Fedry,J. et al.; Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11; Sci Adv (2021) In press; 2021.",10.1126/sciadv.abf5632,"Homo sapiens clone 47D11 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 47D11 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
896,CM17,CM58,MZ049539,MZ049552,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevqkpgasvkvsckvsgytlpelsmhwvrqapgkglewmggfdpedgetfyaqkfqgrvtmtedsstdtaymelsslgsedtavyycataaavrgrgtidywgqgtlvtvss,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvl,"Voss,W.N. et al.; Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes; Science (2021) In press; 2021.",10.1126/science.abg5268,"Homo sapiens isolate CM17 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CM58 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
897,CA521,CA521,MW454371,MW454370,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg*,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec*,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2; Unpublished; 2021.",NaN,"Homo sapiens clone CA521 anti-SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens clone CA521 anti-SARS-CoV-2 immunoglobulin light chain mRNA, partial cds",2022-03-15
898,CV3-1,CV3-1,MW681558,MW681586,SARS-CoV-2,Homo sapiens (human),evqlvesgpevkkpgtsvkvpckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapscsggrcydgfdiwgqgtmvtvss,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvtextartap,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"Homo sapiens isolate CV3-1 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CV3-1 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
899,CV2-75,CV2-75,MW681758,MW681759,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvss,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"Homo sapiens isolate CV2-75 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate CV2-75 immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15
900,H2L2,H2L2,MW579767,MW579768,SARS-CoV,Homo sapiens (human),qvqlqqsgpglvkpsqtlsltcaisgdsvssdsaawnwirqspsrglewlgrtyfrskwnnhyavsvksritinpdtsknqfslllnpvtpedtavyycaratlargaldywgqgtlvtvss,divmtqspdslavslgeratinckssqsvlyssnnmnylawyqqkpgqppklliywastresgvpdrfsgsgpgtdftltisslqaedvavyycqqyystpwtfgqgtkleik,"Wang,C. et al.; A conserved, immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies; Unpublished; 2021.",NaN,"Homo sapiens strain H2L2 clone 1.6c7 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens strain H2L2 clone 1.6c7 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
901,H2L2,H2L2,MW579769,MW579770,SARS-CoV,Homo sapiens (human),qvqlqqsgpglvkpsqtlsltcaisgdnvfsnsaawnwirqspsrglewlgrtyyrskwnndyavsvkgritinpdtyknqfslqlnpvtpedtavyfcarvpmnrggmdvwgqgttvtvss,divmtqspdslavslgeratinckssqsvlassnnmnylawyqqkpgqppklliywasiresgvpdrfsgsgpgtdftltisslqtedvavyychqyysipntfgqgtkleik,"Wang,C. et al.; A conserved, immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies; Unpublished; 2021.",NaN,"Homo sapiens strain H2L2 clone 28d9 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens strain H2L2 clone 28d9 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
902,H2L2,H2L2,MW579771,MW579772,SARS-CoV,Homo sapiens (human),qvqlqqsgpglvkpsqtlsltcaisgdsvssnsvawnwirqsplrglewlgrtyyrskwnndyavsvksriiitpdtsknqfslqlnpvtpedtavyycarvglgkgafdiwgqgtmvtvss,divmtqspdslavslgeratinckssqsvlyrpnknnylgwyqqkpgqppkvliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysipwtfgqgtkvevk,"Wang,C. et al.; A conserved, immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies; Unpublished; 2021.",NaN,"Homo sapiens strain H2L2 clone 18h2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens strain H2L2 clone 18h2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
903,11A,1A,MT943491,MT943518,not determined,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgpdiltgyynyyyygmdvwgqgtmvtvss,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdqgvfgggtkltvl,"Huang,K.-Y.A. et al.; Direct Submission; Submitted (28-AUG-2020) Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, No. 5, Fu-Shin street, Kweishan, Taoyuan 333, Taiwan; 2021.",NaN,"Homo sapiens clone FD 11A heavy chain variable region mRNA, partial cds","Homo sapiens clone FM 1A light chain variable region mRNA, partial cds",2022-03-15
904,COVA2-15,COVA2-15,MT599861,MT599945,SARS-CoV-2,Homo sapiens (human),qvqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewasaisgsggstyyadsvegrftisrdnskntlylqmnslraedtavyycakdtgycgddcyiklirggpdywgqgtlvtvss,divmtqsplslpvtlgqpasiscrssqslvysdgntflnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"Homo sapiens isolate COVA2-15 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds","Homo sapiens isolate COVA2-15 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",2022-03-15
905,COVA1-16,COVA1-16,MT599835,MT599919,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"Homo sapiens isolate COVA1-16 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds","Homo sapiens isolate COVA1-16 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",2022-03-15
906,COVA1-18,COVA1-18,MT599837,MT599921,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarvewaaagtfywgqgtlvtvss,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"Homo sapiens isolate COVA1-18 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds","Homo sapiens isolate COVA1-18 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",2022-03-15
907,BALB/C,BALB/C,MW271801,MW271802,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvss,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleik,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",NaN,"Mus musculus strain BALB/c clone 3C1 anti-SARS-CoV-2 RBD immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone 3C1 anti-SARS-CoV-2 RBD immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
908,BALB/C,BALB/C,MW271803,MW271804,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvss,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleik,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",NaN,"Mus musculus strain BALB/c clone 2H2 anti-SARS-CoV-2 RBD immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone 2H2 anti-SARS-CoV-2 RBD immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
909,JS16,JS01,MW116210,MW116179,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraywgrgptifgvvsnttryygmdvwgqgttvtvss,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprgvtfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"Homo sapiens clone JS16 anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region gene, partial cds","Homo sapiens clone JS01 anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region gene, partial cds",2022-03-15
910,MAB362,MAB362,MT789771,MT789772,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssygmhwvrqapgkglewvaviwydgsdkyyadsvkgrftisrdnskntlylqlnslraedtaiyycareryfdwifdfwgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsswtfgqgtkveik,"Wang,Y. et al.; IgA MAb blocks SARS-CoV-2 spike-ACE2 interaction providing mucosal immunity; Nat Commun (2020) In press; 2020.",NaN,"Homo sapiens MAb362 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens MAb362 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
911,4-8,2-17,MT712278,MT712315,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"Homo sapiens isolate 4-8 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 2-17 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
912,COV2-2196,COV2-2196,MT763531,MT763532,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,"Homo sapiens isolate COV2-2196 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate COV2-2196 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
913,MCOV.2.1H10.G,MCOV.2.1H06.K,MT341590,MT341641,not determined,Mus musculus (house mouse),qvqlkesgpglvapsqslsitctvsgfsltnyaiswvrqppgkglewlgviwtgggtnynsalksrlsiskdnsksqvflkmnslqtddtaryycarisyydyegvdywgqgttltvss,divltqspaslavslgqratiscrasesveyygtslmqwfqqkpgqppkllifaasnvesgvparfggsgsgtdfslnihpveeddiatyfcqqsrkvpwtfgggtkleik,"Ellebedy,A.H. et al.; Direct Submission; Submitted (14-APR-2020) Pathology, Washington University St. Louis, 425 South Euclid, St. Louis, MO 63110, USA; 2020.",NaN,"Mus musculus isolate mCOV.2.1H10.G immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus isolate mCOV.2.1H06.K immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
914,ADI-55688_HC,ADI-56081_LC,MT565750,MT566149,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,ettltqspgtlslspgeratlscrasqsvtsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygraplytfglgtkvdik,"Walker,L.M. et al.; Direct Submission; Submitted (03-JUN-2020) Antibody Sciences, ADIMAB LLC, 7 LUCENT DRIVE, Lebanon, NH 03766, United States; 2020.",NaN,"Homo sapiens isolate ADI-55688_HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate ADI-56081_LC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
915,46472_1,46472_1,MZ126644,MZ126659,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkdgssvkvsceasggtfsdyaiswvrqapgqglewmgriipilgitnyaqqfqtrvtitadkstsavymelsslrskdtaiyycarevnyysafddwgqgtqvtvss,eivmtqspdtlsvspgeratlscrasqnvssnlawyqqkpgqaprlliydastratgiparfsgsgsgteftlaisslqsedfavyycqqynfwwtfgqgtkvdik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_1 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
916,46472_13,46472_13,MZ126656,MZ126671,SARS-CoV,Homo sapiens (human),evqlvesggglvppggslglscaasgftfsefwmswvrqtpgkglewvanigqdgnskyyvdsvkgrftisrdnaksslnlqmnslraedtgvyycarvtivssftnrfdpwgqgvlvtvss,aiqltqspsslsasigdrvtftcrasqdisnflawyqqkpgeppklliysvstlqsgvpsrfsgsgsgtdftltisslqsedlatyycqhrvtfgpgtkvgik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_13 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_13 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
917,46472_2,46472_2,MZ126645,MZ126660,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgyrfitywiswvrqmpgrglewmgkidpsdsstnyspsfqghvaisvdksfntaylqwsrlntsdtamyycaagptgydlltgqyfpyfnywaqgtlvtvss,nfmltqphsvsespgktvsisctrssgsiaskfmqwyqqrpgsaptiliyednlrpsgvpdrfsgsidtssnsalltisglktedeadyycqsyhgsdvvfgggtkltvl,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
918,46472_5,46472_5,MZ126648,MZ126663,SARS-CoV,Homo sapiens (human),qlrlqasgpglvrpsvtlsltcavsgasvksdksywgwfrqspgkglasiatiyyngnvyynpslksrvtlsldtstnqlslkmrsvtaadtaiyycarldyskqtwgqgilvtvss,divmtqsprslpvtpgepasiscrssqslvhtngynyldwylqkpgqspqlliylasnrasgvpgrfsgsgsgtdftlkisrveaddvgvyycmqalqtpltfgggtrleik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_5 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_5 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
919,46472_3,46472_3,MZ126646,MZ126661,SARS-CoV,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsvypmhwvrqapgrglewvavisydgsnqyyadsvrgrftisrdnskntlylhmnslrpedtavfycardrsatyygpfdywgqgtlvtvss,sseltqdpavsvalgqtvritcqgdslrsysaswyqqkpsqapvlviyannnrpsgipdrfsgsnsgntasltitgaqaedeadyycnsrdnsgnhpvifgggttltvl,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_3 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_3 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
920,46472_9,46472_9,MZ126652,MZ126667,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsetlsltciisggsvssgsyywswirqppgkgleyigyifysgntnynpslksrvtisvdtsknqfslrltsvtaadtavyhcaslptygsgrwgidswgqgtlvtvss,diqmtqspssvsasvgdrvtitcrasqdisiwltwyqqrpgkapklliyaasalqrgvpsrfsgsgsgtdftltisslqpedfttyfcqqgnsfpltfgggtkveik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_9 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_9 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
921,46472_4,46472_4,MZ126647,MZ126662,SARS-CoV,Homo sapiens (human),evpllesggglvqpggslrlscvasgfpfssfalswvrqapgkglewvstintnggttyyldsvkgrftvsrdnskntlflqmsslraedtaiyycakdllshsgtysagstfdywgqgtlvivss,diqmtqspsslsasvgdrvtitcrasqsigvylnwyqqkpgkapkllihatsnlqsgvpsrfscsgsgteftltisslqpedfatyycqesystntfgqgtkleik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_4 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_4 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
922,46472_15,46472_15,MZ126658,MZ126673,SARS-CoV,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyalnwvrqapgqglewmgwinintgkptyaqgftgrfvlsldtsvstaylqisslkaedtavyycardfdlvvpsatyppfyyhgmdvwgqgttvtvss,sseltqdpavsvalgqtvritcqgdslrtyyaswyqqkpgqapilviygknkrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgdqtfyvfgtgtqvtvl,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_15 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_15 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
923,46472_6,46472_6,MZ126649,MZ126664,SARS-CoV,Homo sapiens (human),qlqlqesgpglvkpsetlflfcsvsggsisisthywewirqppgkglewigsfyssgttyynpslkgrvtisadtsksqislkmssvtaadtavyycarrpqylllsmttgrrhhdfvmdvwgqgttvtvss,divmtqspdslavslgeratitckssqsvlfgsnnenylawyqkkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyntprtfgqgtkvevk,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_6 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_6 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
924,46472_7,46472_7,MZ126650,MZ126665,SARS-CoV,Homo sapiens (human),gvqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsginvngydtyyadsvkgrftisrdnskntlflqmisltaedtalyycvkedtplvfdswgqgtlvtvss,diqmtqspstlsasvgdrvtitcrasqfinswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltinslqpddfatyycqqydsystfgqgtkveik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_7 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_7 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
925,46472_12,46472_12,MZ126655,MZ126670,SARS-CoV,Homo sapiens (human),qvqlvqsgaevqkpgasvkvsckasgyrfdifdinwvrqasgqgpewmgwmnpnsgntgyahkfqgrvtmtrdsstntaymelssltfedtavyycardrvertgnvgfgyyamdvwgqgttvivss,diqmtqspsslsasvgdrvtitcrasqsitnylnwyqqrpgkaprlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfgtfycqqtysspsytfgqgtklemk,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_12 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_12 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
926,46472_11,46472_11,MZ126654,MZ126669,SARS-CoV,Homo sapiens (human),egqllesggglvqpggslrlsceasgftfsryamtwirqapgkglewvssitaipydrfyadslyadsvkgrftisrddsknmvylqanslrvedtavyycvkmrtavvgvtplwgqgtlvtvss,aiqvtqspsslsasvgdrititcrtsqgirddlgwyqqkpgkaptlliygatnlqsgvpsrfsgsesgtdftltisslqpedfatyyclqdynylfsfgpgtkvdik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_11 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_11 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
927,46472_10,46472_10,MZ126653,MZ126668,SARS-CoV,Homo sapiens (human),evhlvesgggliqpggslklscaasgfavsgyymiwvrqapgkglewvsviftsgrtyyadsakgrftisrdsskntlylqmdslraedtavyycagflpvynngwsyfdswgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgsrpnignnkvnwyqqlpgtapkvliygnnqrpsgvpdrfsgsksatsaslaisglqsedeadyycavwddslngpvfgggtkltvl,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_10 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_10 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
928,46472_14,46472_14,MZ126657,MZ126672,SARS-CoV,Homo sapiens (human),evllvesgggviqpgaslrlscepsgttvssnfwtwvrqapgrrlehvaiiysgdatyyadsvkgrftifrdnsknmlflemnnlkvadsaiyfcvrgrtywgqgtlvsvss,eivmtqspatlslspgdtatlscrasqsvasnlawyqqkpgqaprllvsgastratgipprfsgsgsgteftltisslqsedfavyycqqynrwlwtfgqgtkveik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_14 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_14 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
929,46472_8,46472_8,MZ126651,MZ126666,SARS-CoV,Homo sapiens (human),evqlvesgggfiqpggsvrlscsasgfnvydnyfswvrqapgrgpewvsviyrdgatryaesvqgrftmfrdnsrktlylqmnrlkagdtavyfcalgrkdygdyyrwgqgtlvtvss,eivltqspgtlslspgetatlscragqsvrsrflawyqqkpgqsprvliygasnrasgvpdrfsgsgsgtdftltitrlepedvavyycqqyapsppwyifgqgtkleik,"Shiakolas,A.R. et al.; Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions; Cell Rep Med, 100313 (2021) In press; 2021.",10.1016/j.xcrm.2021.100313,"Homo sapiens isolate 46472_8 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 46472_8 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
930,CNC2T1P1_B10,MNC5T2P1_G1,MT658806,MT658861,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvsgydssgywgdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqhkpgqaprllicgassratgipdrfsgsgsgtgftltisrlepedfavyycqqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"Homo sapiens clone CnC2t1p1_B10 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone MnC5t2p1_G1 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
931,27D,27D,AY530316,AY530323,SARS-CoV,Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarnfgedfdywgqgtlvtvss,sqsaltqpasvsgspgqsitisctgtssdlgghnfvswyqqhpgkapklmiydvfnrpsgvssrfsgsksgntasltisglqaedeadyfcssytitnivvfgrgtkltvlgq,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 27D anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 27D anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
932,12E,12E,AY530314,AY530321,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvgyygdyawgyyyygmdvwgqgtlvtvss,syeltqppsasgtpgqrvtiscsgssssigsetvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyyctawddtlngrvifgggtkltvlg,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 12E anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 12E anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
933,8C,8C,AY530313,AY530320,SARS-CoV,Homo sapiens (human),evqlvqsggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtgvyycardwgysfgdwgqgtlvtvss,iqmtqspsslsasvgdrvtitcratqsisthlnwyqqrggkapklliygastlesgvpsrfsgsgsgteftltisslqpedfatyyclqhrsypwtfgqgtnveik,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 8C anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 8C anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
934,80R,80R,AY530317,AY530324,SARS-CoV,Homo sapiens (human),evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,ttltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 80R anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 80R anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
935,91M,91M,AY530318,AY530325,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfssswmswvrqapgkglewvayikqdgsekyyvdsvkgrftisrdnaknslylqmdslraedtavyycardqgwgwdgteyysdywgqgtlvtvss,sqsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyfcssytitdivvfgggtkltvlr,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 91M anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 91M anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
936,26H,26H,AY530315,AY530322,SARS-CoV,Homo sapiens (human),qvqlqesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarerwlqigedafdiwgqgttvtvss,qtvvtqepsfsvspggtitltcdlnsglvssshypswyqqtpgqaprtliyntnirssgvpdrfsgailgnkaaltitgaqaedesdyycvlymgsgisvfgggtkltvlgq,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 26H anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 26H anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
937,92N,92N,AY530319,AY530326,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarddlsdygewlgpdywgqgtlvtvss,qpgltqppsasgtpgqrvtiscsgsrsniggntvnwyqhvpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglrsedeaeyycatwedslsgyvfgpgtkvtvlg,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 92N anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 92N anti-SARS S protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
938,03-001,03-001,AY554173,AY554181,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisggstyyadsrkgrftisrdnskntlylqmnnlraedtavyycarhrfrhvfdywgqgtlvtvle,eltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtkveik,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-001 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 03-001 anti-SARS-CoV immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
939,03-015,03-015,AY554179,AY554183,SARS-CoV,Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtavyycarglslrpwgqgtlvtvsr,seltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhvvfgggtkltvl,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-015 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 03-015 anti-SARS-CoV immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15
940,03-006,03-006,AY554175,AY554182,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsgypmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgsprtpsfdywgqgtlvtvle,diqmtqsphslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvgvyycqqrfrtpvtfgqgtkleik,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-006 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone 03-006 anti-SARS-CoV immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
941,CV1,CV48,MT462477,MT462570,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdkfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"Homo sapiens isolate CV1 anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Homo sapiens isolate CV48 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
942,P054_050,P003_001,MW802487,MW802274,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqptgqdlewvsaigtagdtyypdsvkgrftisrenaknssylqmnslragdtavyycarasfdssgylnyfdywgqgtlvtvss,eivltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygssrntfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"Homo sapiens isolate P054_050 anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate P003_001 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
943,BALB/C,BALB/C,MZ703121,MZ703122,SARS-CoV,Mus musculus (house mouse),avqlqesgpdlvkpsqslsltctvtgfsitsaytwhwirqfpgnklewmgyihysgytyynpslksrisitrdtsknqfflqlnsvttedtatyycarrhdfysldcwgqgtsvtvss,dikmtqspssmyvslgervtitckasqdiysylnwfqrkpgkspktliyranslvdgvpsrfsgsgsgqdysltissleyedmgiyyclqydefpytfgggtkleik,"VanBlargan,L.A. et al.; Direct Submission; Submitted (03-AUG-2021) Internal Medicine, Washington University in St Louis, 425 S. Euclid Ave, St Louis, MO 63110, USA; 2021.",NaN,"Mus musculus strain BALB/c clone SARS2-02 immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone SARS2-02 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
944,BALB/C,BALB/C,MZ703123,MZ703124,SARS-CoV,Mus musculus (house mouse),qvqlkesgpglvapsqslsitctvsgfsltrygvhwvrqppgkglewlgviwadgstyynsalmsrlsiskdnsksqvflnmnslqtddtakyycardgrgyddywgqgttltvss,qivltqspaimsaspgekvtmtcsasstvsfiywyqqkpgssprlliydtsnpasgvpvrfsgsgcgtsyyltisrmeaedaatyycqqwntypltfgagtklelk,"VanBlargan,L.A. et al.; Direct Submission; Submitted (03-AUG-2021) Internal Medicine, Washington University in St Louis, 425 S. Euclid Ave, St Louis, MO 63110, USA; 2021.",NaN,"Mus musculus strain BALB/c clone SARS2-38 immunoglobulin heavy chain variable region mRNA, partial cds","Mus musculus strain BALB/c clone SARS2-38 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
945,F26G18,F26G18,AY605269,AY605278,SARS-CoV,Mus musculus (house mouse),lvqleesgtvlprpgasvkmsckasgytftsywmhwvkqrpgqglewigaiypgnsdtnynqkfkgratltavtststasmelssltnedsavyyctrdgygslyyyamdfwgqgtsvtvssakttapsvkg,elvmtqspsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhagvpsrfsgsgsgtdysltisnleqediatyfcqqgytlpytfgggtkleikradaaptvs,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G18 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus clone F26G18 immunoglobulin gamma light chain variable region mRNA, partial cds",2022-03-15
946,F26G9,F26G9,AY605267,AY605276,SARS-CoV,Mus musculus (house mouse),vqllesgtvlarpgasvkmsckasgysftsywmhwvkqrpgqglewigaiypgnsdtsynqkfkgkakltavtsastaymelssltnedsavyyctrsvyygygyfdvwgagttvtvssakttppsv,dilmtqshkcmstsvgdrvsitckasqdvstavvwyqqkpgqfpklliywastrhtgvpdrftgsgsgtdytltissvqaedlalyycqqhyttpytfgggtkleikradaaptvs,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G9 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus clone F26G9 immunoglobulin gamma light chain variable region mRNA, partial cds",2022-03-15
947,F26G19,F26G19,AY605270,AY605279,SARS-CoV,Mus musculus (house mouse),evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvssakttapsvypla,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleikradaaptv,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G19 immunoglobulin gamma heavy chain variable region mRNA, partial cds","Mus musculus clone F26G19 immunoglobulin gamma light chain variable region mRNA, partial cds",2022-03-15
948,COV2-2164,COV2-2164,MZ555629,MZ555630,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkvei,"Chen,E.C. et al.; Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals; Cell Rep (2021) In press; 2021.",NaN,"Homo sapiens isolate COV2-2164 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens isolate COV2-2164 immunoglobulin light chain mRNA, partial cds",2022-03-15
949,CV38-142,CV38-142,MW002785,MW002803,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkiscqgsgysftsywigwvrqmpgkglewmgiiypgesdtrysssfqghvtisadksistaylqwsslkasdtamyycarirgvyssgwiggdywgqgtlvtvssas,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprqwtfgqgtkveik,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.049,"Homo sapiens clone CV38-142 anti SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens clone CV38-142 anti SARS-CoV-2 immunoglobulin kappa chain mRNA, partial cds",2022-03-15
950,54042-11,54042-11,MZ820103,MZ820112,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgvnvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmislraddtavyycardlvyygmdvwgqgttvtvss,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqvdsyspftfgpgtkvdik,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-11 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-11 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
951,54042-3,54042-3,MZ820098,MZ820107,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsskymswvrqapgkglvcvsliyggdstyyadsvrgrftisrdsskntlylqmnslraedtavyycarvhfryyddsgyyeanpwffdlwgrgtpvtvss,qsvltqppsvsgapgqrvtiscagsssniganydvhwyqvlpgaapkllifrnnnrpsgvpdrfsgsksvtsaslaitglqaedeadyycqsydsslsawvfgggtkltvl,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-3 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-3 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
952,54042-15,54042-15,MZ820105,MZ820114,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgfifddyamhwvrqvpgkglewvsgvdwnsgtigyadsvkgrfiisrdnaknslylhmrslrvedtafyycakdrlktgpgyfdlwgrgtlvtvss,eivltqspatlslspgeratlscrasqsvsnylawyqqrpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrsdwltfgggtnveik,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-15 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-15 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
953,54042-5,54042-5,MZ820100,MZ820109,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslsthgmsvswirqppgkalqwlaridwdddkfystslktrltiskdtsknqvvltmtnldpvdtatyycarvrlggfdyymdvwgkgttvtvss,qsvltqppsvsaapgqkvtiscsgtrsnignnyvswyqqlpgtapklliydntkrpsgipdrfsgsrsgtsatlgitglqtgdeadyycgtwdnnlntgvfgggtkltvl,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-5 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-5 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
954,54042-4,54042-4,MZ820099,MZ820108,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstigvgvswirqppgkaldwlaliywdddkryspslksrltvtmdtsknqvvltltnmdpvdtatyfcahglfsssdwggldvwgqgttvtvss,dmqmtqspsslsasvgdrvtitcrasqsvftylnwyqqkpgkapklliyaasrlqsgvpsrfrgsgsgtdftltisslqpedfatyycqqshstpfifgpgtkvdik,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-4 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-4 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
955,54042-2,54042-2,MZ820097,MZ820106,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfafsnyamhwvrqapgkglewvavaphnrtdkyyadsvrgrftisrdtskntlyllmnsltvedtglyycakddgyclgrgcyyapgphwgqgtlvtvss,syeltqppsvsvspgqaaritcsgdalpekyaywyqqksgqapvlliyedfkrpseiperfsgsssgtvatltisgaqvddegdyycystdssgnqnyvfgtgtkvtvl,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-2 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
956,54042-7,54042-7,MZ820101,MZ820110,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdlvqpgrslrlscaasgftfeyyamhwvrqppgkglewvsgigwnrgslgyadsvkgrftisrddaksslylqmnslrtedtafyycvrgfreflktsgpndywgqgtlvtvss,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqvpgtapklliydnhsrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdgslsvyvfgsgtkvtvl,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-7 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-7 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
957,54042-10,54042-10,MZ820102,MZ820111,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasglivsrnymtwvrqapgrglewvstiyaggsafyadsvkgrftisrdnskntlylqmnslraedtavyycardlnvrggldvwgqgttvtvss,diqltqspsflsasvgdrvtitcrasqginnylawyqqkpgkapkllifaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdpaltfgggtkveik,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-10 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-10 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
958,54042-14,54042-14,MZ820104,MZ820113,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscsasgftfsnygmhwvrqapgkglewvaviwfdgnnkyyansvkgrftisrdnskntlylqmktlraedtavyycakdtwdvpaanppysfyymdvwgmgttvtvss,etvltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrstlitfgqgtrleik,"Kramer,K.J. et al.; Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition; Unpublished; 2021.",NaN,"Homo sapiens isolate 54042-14 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate 54042-14 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
960,C81C10,C81E12,MW718328,MW718631,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycavmeysgydslrpldywgqgtlvtvss,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrvfgggtkltvl,"Tong,P. et al.; Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike; Cell (2021) In press; 2021.",https://doi.org/10.1016/j.cell.2021.07.025,"Homo sapiens clone C81C10 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone C81E12 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15
961,R40-1A1,R849-3H2,OL741060,OL741311,SARS-CoV-2,Homo sapiens (human),qahlvqsgpevkkpgasvkvsckasgyafttfaiswvrqapghglewmgrinpyngktyyaqkvqgrvtmttetststaymevrslrsddtavyycarqypmprgphynymdvwgkgtavtvss,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapqlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystwtfgqgtkveir,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"Homo sapiens isolate R40-1A1 immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens isolate R849-3H2 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
962,NT-193,NT-193,MW619742,MW619743,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargwdldyyygmdvwgqgttvtvss,airmtqspsamsasvgdrvtvtcrasqgignylawfqlkpgkvpkrliyaasslqsgvparfsgggsgteftltisslqpedfatyyclqhgflpwtfgqgtkleik,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.025,"Homo sapiens clone NT-193 immunoglogulin heavy chain variable region mRNA, partial cds","Homo sapiens clone NT-193 immunoglogulin light chain variable region mRNA, partial cds",2022-03-15
963,NT-108,NT-108,MW619740,MW619741,SARS-CoV-2,Homo sapiens (human),evqlqqsgpglvkpsqtlsltcsisgdsvssnsaawnwirqspsrglewlgrtyyrskwyndyagtvksriainpdtsknqfslhlnsvtpedtavyfcarvisvagyafdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsstflawyqqkpgqaprlliygasymatgipdrfsgsgsgtdftltisrlepedfavyycqqygssltfgggtkleik,"Onodera,T. et al.; A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.025,"Homo sapiens clone NT-108 immunoglogulin heavy chain variable region mRNA, partial cds","Homo sapiens clone NT-108 immunoglogulin light chain variable region mRNA, partial cds",2022-03-15
964,10-121,9-105,MZ089617,MZ089626,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvsrnymswvrqapgrglewvsliysggstyyadsvkgrftisrdsskntlylqmnslraedtavyycarpivgaragmdvwgqgttvtvss,divmtqspgtlslspgeratlscrasqsvpsiylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Kaku,Y. et al.; Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19; Cell Rep 36 (2), 109385 (2021); 2021.",10.1016/j.celrep.2021.109385,"Homo sapiens clone 10-121 anti SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds","Homo sapiens clone 9-105 anti SARS-CoV-2 immunoglobulin kappa light chain mRNA, partial cds",2022-03-15
965,DH715.1VH,DH1011VK,MT470283,MT470354,not determined,Macaca mulatta (Rhesus monkey),qvklqesgpglvkpsetlsltcgvsggsisggydwswirqppgkglewigyvyyngghpyynpslnnrvtisidtskkyfsleltsvtaadtavyycarsyspdglylytsldlwgrgvlvtvss,divmtqtplsspvtlgqpasiscrssedlahsdgntylswlhqrpgqpprlliykiskrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqltqfprtfgqgtkveik,"Williams,W.B. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020) In press; 2020.",10.1101/2020.06.30.178921,"Macaca mulatta clone DH715.1VH immunoglobulin heavy chain variable region mRNA, partial cds","Homo sapiens clone DH1011VK immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15
967,B6,NaN,7R98_F,NaN,SARS-CoV-2,Lama glama (llama),maevqlqasggglvqagdslrlscvavsgrtistfamgwfrqapgkerefvatinwsgssaryadpvegrftisrddakntvylemsslkpgdsavyycasgrylggitsysqgdfapwgqgtqvtvssaaalehhhhhh,NaN,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,"Chain F, Nanobody B6",NaN,2022-03-15
970,E2,NaN,7N0I_L,NaN,SARS-CoV-2,Lama glama (llama),maevqlqasggglvqaggslrlscaasgrtdstqhmawfrqapgkerefvtaiqwrgggtsytdsvkgrftisrdnakntvylemnslkpedtavyycatntrwtyfsptvpdrydywgqgtqvtvssaaalehhhhhh,NaN,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,"Chain L, Single-domain antibody E2",NaN,2022-03-15
974,C2,NaN,7N0R_D,NaN,SARS-CoV-2,Lama glama (llama),maevqlqasggglvrpggslrlscaasgftfssyammwvrqapgkglewvsainggggstsyadsvkgrftisrdnakntlylqmnslkpedtavyycakyqaavhqekedywgqgtqvtvssaaalehhhhhh,NaN,"Ye,Q. et al.; Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies; bioRxiv (2021); 2021.",10.1101/2021.06.01.446591,"Chain D, Single-domain antibody C2",NaN,2022-03-15
976,NaN,NaN,6ZCZ_F,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvssgpggqhhhhhhgaeqkliseedls,NaN,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.",10.1038/s41594-020-0480-y,"Chain F, Nanobody",NaN,2022-03-15
977,E4,NaN,7VMU_A,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgvtvssnymswvrqapgrglewvsliypggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycardlsekggmdvwgqgttvtvssggggsggggsggggsggggasdivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyprfgpgtkveik,NaN,"Li,L. et al.; Antibody engineering improves neutralization activity against K417 spike mutant variants of SARS-CoV-2; Unpublished; 2021.",NaN,"Chain A, scFv E4",NaN,2022-03-15
978,FD20THE,NaN,7CYV_H,NaN,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),gsssqqvqlqqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmgriipilgianyaqkfqgrvtitadiststaymalsslrsedtavyycakvevnigmddyyyyygmdvwgqgttvtvssgggsggggsggggssyvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvlsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; Structural insight from a neutralizing human scFv in complex with RBD suggest a new site of vulnerability for SARS-CoV-2; Unpublished; 2021.",NaN,"Chain H, The heavy chain variable region of the scFv FD20,The light chain variable region of the scFv FD20",NaN,2022-03-15
979,RE9F06,NaN,7OLZ_B,NaN,SARS-CoV-2,Vicugna pacos (alpaca),gsqvqlvesggglvqaggslrlscaasgrtfsndalgwfrqaprkerefvaainwnsgtyyadsvkgrftisrdnakntvylqmnslkpedtavyscaaasdyglpredflydywgqgtqvtvssts,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,"Chain B, Nanobody Re9F06",NaN,2022-03-15
980,RE5D06,NaN,7OLZ_C,NaN,SARS-CoV-2,Vicugna pacos (alpaca),gsqvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvssts,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,"Chain C, Nanobody Re5D06",NaN,2022-03-15
981,F2,NaN,7OAY_LLL,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqaggslrlaciasgrtfhsyvmawfrqapgkerefvaaiswsstptyygesvkgrftisrdnakntvylqmnrlkpedtavyfcaadrgesyyytrpteyefwgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain LLL, F2 nanobody",NaN,2022-03-15
987,H3,NaN,7OAP_FFF,NaN,SARS-CoV-2,Lama glama (llama),maqvqlvesggglvktggslrlscaasgrtfstysmgwfrqapgkerefvagmrwtgsstfysdsvkgrftvsrnnakdtvylhmnslkpedtavyycaittivrayyteyteadfgswgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, H3 nanobody",NaN,2022-03-15
988,C1,NaN,7OAP_AAA,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain AAA, C1 nanobody",NaN,2022-03-15
989,C5,NaN,7OAO_FFF,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, C5 nanobody",NaN,2022-03-15
990,NB17,NaN,7N9T_F,NaN,SARS-CoV-2,Lama glama (llama),hvqlvesggglvqaggslrlscaasgsifssnamswyrqapgkqrelvasitsggnadyadsvkgrftisrdkntvypemsslkpadtavyychavgqeasayapraywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain F, Nanobody Nb17",NaN,2022-03-15
993,NB36,NaN,7MEJ_B,NaN,SARS-CoV-2,Lama glama (llama),vqlvesggglvqaggsltltcaasgrtfssetmdmgwfrqapgkerefvaadswndgstyyadsvkgrftisrdsakntlylqmnslkpedtavyycaaetysiyekddswgywgqgtqvtvs,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain B, Nanobody Nb36",NaN,2022-03-15
994,NB21,NaN,7MEJ_A,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain A, Nanobody Nb21",NaN,2022-03-15
995,NB105,NaN,7ME7_B,NaN,SARS-CoV-2,Lama glama (llama),vqlvesggglvqaggslrlscavsgrtfstygmawfrqapgkerdfvatitrsgettlyadsvkgrftisrdnakntvylqmnslkiedtavyycavrrdsswgysrdlfeydywgqgtqvtvs,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain B, Nanobody Nb105",NaN,2022-03-15
998,SYBODY#68,NaN,7P7A_D,NaN,SARS-CoV-2,synthetic construct,qvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,NaN,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.",NaN,"Chain D, sybody#68",NaN,2022-03-15
1000,SYBODY#15,NaN,7P79_H,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvknfemewyrkapgkerewvaaiqsggvetyyadsvkgrftisrdnakntvylqmnslkpedtavyycfvyvgrsyigqgtqvtvs,NaN,"Walter,J.D. et al.; Bispecific sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug-resistance; bioRxiv (2020); 2021.",NaN,"Chain H, sybody#15",NaN,2022-03-15
1014,NB34,NaN,7N9E_D,NaN,SARS-CoV-2,Lama glama (llama),masmtggqqmgrdpnsdvqlvesggglvqaggslrlscaasgftfsnyvmywgrqapgkgrewvsgidsdgsdtayassvkgrftisrdnakntlylqmnnlkpedtalyycvkskdpygspwtrsefddywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain D, Nb34 nanobody",NaN,2022-03-15
1015,NB95,NaN,7N9C_E,NaN,SARS-CoV-2,Lama glama (llama),masmtggqqmgrdpnsqvqlvesggglvqaggslrlscaasgrtfssysmgwfrqaqgkerefvatingngrdtyytnsvkgrftisrddatntvylqmnslkpedtaiyycaadkdvyygytsfpneyeywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain E, Nanobody NB95",NaN,2022-03-15
1017,NB21,NaN,7N9B_F,NaN,SARS-CoV-2,Lama glama (llama),masmtggqqmgrdpnsqvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvssklaaalehhhhhh,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain F, NB21 Nanobody",NaN,2022-03-15
1020,NB12,NaN,7MY3_D,NaN,SARS-CoV-2,Mus musculus (house mouse),qvkleesgggsvqaggslrlictapglthnncgldwyrrapgkerefvssisadgttsyadsvkgrftiskdkvedtvylqmnslkpedtaiyscktafpyfgnscvldywgqgtsvtvsshhhhhh,NaN,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.",10.1038/s41586-021-03676-z,"Chain D, Nanobody Nb12",NaN,2022-03-15
1023,NB30,NaN,7MY2_D,NaN,SARS-CoV-2,Mus musculus (house mouse),qvqlvesggglvqaggslrlscaasgltfskyamgwfrqapgkerkfvatiswsgdsafyadsvkgrftisrdnarntvylqmnslkpedtavyycaadrgmgygdfmdywgqgtsvtassasgahhhhhh,NaN,"Xu,J. et al.; Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants; Nature 595 (7866), 278-282 (2021); 2021.",10.1038/s41586-021-03676-z,"Chain D, Nanobody Nb30",NaN,2022-03-15
1026,SB45,NaN,7N0H_Z,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,"Chain Z, Synthetic nanobody (Sb45)",NaN,2022-03-15
1031,#68,NaN,7MFU_F,NaN,SARS-CoV-2,synthetic construct,ssqvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,"Chain F, Synthetic nanobody #68 (Sb68)",NaN,2022-03-15
1032,#14,NaN,7MFU_E,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvqaremewyrqapgkerewvaaikstgtytayaysvkgrftisrdnakntvylqmnslkpedtavyycyvyvgssyigqgtqvtvsa,NaN,"Ahmad,J. et al.; Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction; J Biol Chem 297 (4), 101202 (2021); 2021.",10.1016/j.jbc.2021.101202,"Chain E, Synthetic Nanobody #14 (Sb14)",NaN,2022-03-15
1035,NaN,NaN,7B14_D,NaN,SARS-CoV-2,Camelus bactrianus (Bactrian camel),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain D, Nanobody against SARS-CoV-2",NaN,2022-03-15
1036,NaN,NaN,7DEU_B,NaN,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmhwvkqshgkslewigginpnngdntynqklkgkatltvhkssstaymelrsltsedsavyycardgypyyyaldywgqgtsvtvssggggsggggsggggsdivmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkpliysassrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynnypwtfgggtkleikaaahhhhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,"Chain B, antibody scFv",NaN,2022-03-15
1037,NaN,NaN,7DET_D,NaN,SARS-CoV-2,Mus musculus (house mouse),mkflvnvalvfmvvyisyiyadgsqvqlvqsgaevkkpgasvklsckasgysftsywvnwvrqapgqglewigmihpsdsetrlnqkfkdrvtitvdkststaymelsslrsedtavyycaradgyewyfdvwgrgtlvtvssggggsggggsggggsdivltqspaslavspgqratitcrasesvdsygnsfmhwyqqkpgqppklliyrasnlesgiparfsgsgsgtdftltinpveandvanyycqqsnedpwtfgqgtkveikaaahhhhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,"Chain D, antibody scFv",NaN,2022-03-15
1039,NaN,NaN,7DEO_C,NaN,SARS-CoV-2,Homo sapiens (human),gsevqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnrfyadsvkgrftisrdnskstlylqmnslraedtavyycatdppglrfrfdywgqgtlvtvssggggsggggsggggsdivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikgggshhhhhh,NaN,"Fu,D. et al.; Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes; PLoS Biol 19 (5), e3001209 (2021); 2021.",10.1371/journal.pbio.3001209,"Chain C, antibody scFv",NaN,2022-03-15
1041,MR17-SR31,NaN,7D30_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvsggggsggggsggggsggggsggggsggggsgsssqvqlvesggglvqaggslrlscaasgfpvwqgemawyrqapgkerewvaaissmgyktyyadsvkgrftisrdnakntvylqmnslkpedtavyycavmvgfwyagqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Yao,H. et al.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2; PLoS Pathog 17 (3), e1009328 (2021); 2021.",10.1371/journal.ppat.1009328,"Chain A, sybody fusion of MR17-SR31 with a GS linker",NaN,2022-03-15
1042,GLAMASARS-COV-2,NaN,7B17_B,NaN,SARS-CoV-2,synthetic construct,qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssggggsggggsggggsqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssggypydvpdyaghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain B, SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama,SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama",NaN,2022-03-15
1043,SB68,NaN,7KLW_C,NaN,SARS-CoV-2,synthetic construct,sssqvqlvesgggsvqaggslrlscaasgsissitylgwfrqapgkeregvaalitvnghtyyadsvkgrftvsldnakntvylqmnslkpedtalyycaaaawgyawplhqddywywgqgtqvtvs,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain C, SB68, Synthetic nanobody",NaN,2022-03-15
1044,SB45,NaN,7KLW_B,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvyrdrmawyrqapgkerewvaaiysagqqtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkdvghhyeyydywgqgtqvtvs,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain B, SB45, Synthetic Nanobody",NaN,2022-03-15
1045,SB16,NaN,7KGK_B,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsagra,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain B, Sb16, Sybody-16, Synthetic Nanobody",NaN,2022-03-15
1047,NaN,NaN,7KSG_F,NaN,SARS-CoV-2,Lama glama (llama),qvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain F, Nanobody against SARS-CoV-2 glycoprotein",NaN,2022-03-15
1050,NM1230,NaN,7B27_DDD,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvrpggslrlscvgsgftfsgyamnwyrqapgkalelvagisnagdlthyeepmkgrvaisrandkntvylqmddlkpedtavyrchapgvrvgtgerkdvwgqgaqvtvsseqkliseedlkkkhhhhhh,NaN,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.",10.15252/embr.202052325,"Chain DDD, neutralizing nanobody NM1230",NaN,2022-03-15
1052,NM1226,NaN,7NKT_BBB,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesgggsvqpggslrlsclgsgsldyyaigwfrqapgkeregvsciassgdrtiyadsvkgrftisrdygkntvylqmnslkpedtamyycaalqgsyyytgfvaneydywgqgapvtvsseqkliseedlkkkhhhhhh,NaN,"Wagner,T.R. et al.; NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies; EMBO Rep 22 (5), e52325 (2021); 2021.",10.15252/embr.202052325,"Chain BBB, neutralizing nanobody NM1226",NaN,2022-03-15
1053,NaN,NaN,7B18_I,NaN,"SARS-CoV-2, Spike protein",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain I, Nanobody against spike glycoprotein VHH V",NaN,2022-03-15
1054,NaN,NaN,7B18_H,NaN,SARS-CoV-2,Lama glama (llama),sqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain H, Nanobody against SARS-CoV-2 VHH E",NaN,2022-03-15
1059,H11-H4,NaN,6ZH9_FFF,NaN,"SARS-CoV-2, Spike protein RBD",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.",10.1038/s41594-020-0469-6,"Chain FFF, Nanobody H11-H4",NaN,2022-03-15
1060,NaN,NaN,7KN7_B,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssgdsthyvdsvkgrftisrdnakntvylqmnslkpedtavyycaaqsgsyywcgsdwheydyrgqgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain B, VHH W",NaN,2022-03-15
1061,NaN,NaN,7KN6_C,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssgglpetgghhhhhh,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain C, VHH V",NaN,2022-03-15
1062,NaN,NaN,7KN5_F,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlvesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssggsthfadsvkgrftisrdnakntvylqmnslipedtavyycaaqsgsyywcgsdwheyeywgqgtqvtvss,NaN,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.",10.1126/science.abe6230,"Chain F, VHH U",NaN,2022-03-15
1066,NB20,NaN,7JVB_D,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,NaN,"Xiang,Y. et al.; Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2; Science 370 (6523), 1479-1484 (2020); 2020.",10.1126/science.abe4747,"Chain D, Nanobody Nb20",NaN,2022-03-15
1068,NaN,NaN,7A25_F,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,NaN,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.",NaN,"Chain F, Sybody 23",NaN,2022-03-15
1071,MNB6,NaN,7KKL_F,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspaygdywgqgtqvtvsshhhhhh,NaN,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.",10.1126/science.abe3255,"Chain F, Synthetic nanobody mNb6",NaN,2022-03-15
1074,NB6,NaN,7KKK_F,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqaggslrlscaasgiifgrnamgwyrqapgkerelvagitrrgsityyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpaspapgdywgqgtqvtvss,NaN,"Schoof,M. et al.; An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike; Science 370 (6523), 1473-1479 (2020); 2020.",10.1126/science.abe3255,"Chain F, Synthetic nanobody Nb6",NaN,2022-03-15
1077,SB23,NaN,7A29_F,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvesenmhwyrqapgkerewvaaiystggwtlyadsvkgrftisrdnakntvylqmnslkpedtavyycavqvgywyegqgtqvtvs,NaN,"Custodio,T.F. et al.; Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2; BiorXiv (2020); 2020.",NaN,"Chain F, Neutralising sybody (Sb23)",NaN,2022-03-15
1080,TY1,NaN,6ZXN_F,NaN,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvssgglpetgghhhhhh,NaN,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; BioRxiv (2020); 2020.",NaN,"Chain F, Nanobody Ty1",NaN,2022-03-15
1083,VHH-55,NaN,6WAR_P,NaN,SARS-CoV,Lama glama (llama),qvqlqesgggsvqaggslrlscvasgsifsinamdwyrqapgkqrelvagitsggstnygdfvkgrftisrdnakntvylqmdslkpedtavyycaaevggwgpprpdywghgtqvtvssgslevlfq,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.",10.1016/j.cell.2020.04.031,"Chain P, nanobody MERS VHH-55",NaN,2022-03-15
1091,MR17-K99Y,NaN,7CAN_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvyddgqlayhydywgqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,"Chain A, sybody MR17-K99Y",NaN,2022-03-15
1092,MR17,NaN,7C8W_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,qvqlvesggglvqaggslrlscaasgfpvevwrmewyrqapgkeregvaaiesyghgtryadsvkgrftisrdnakntvylqmnslkpedtavyycnvkddgqlayhydywgqgtqvtvsag,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,"Chain A, Synthetic nanobody MR17",NaN,2022-03-15
1093,SR4,NaN,7C8V_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvyswnmwwyrqapgkerewvaaieshgdstryadsvkgrftisrdnakntvylqmnslkpedtavyycyvwvghtyygqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Li,T. et al.; A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection; Nat Commun 12 (1), 4635 (2021); 2020.",10.1038/s41467-021-24905-z,"Chain A, Synthetic nanobody SR4",NaN,2022-03-15
1094,NaN,NaN,7KM5_D,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqglewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgheldhwgqgtqvtvsshhhhhh,NaN,"Ye,G. et al.; The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates; Elife 10, e64815 (2021); 2021.",10.7554/eLife.64815,"Chain D, nanobody",NaN,2022-03-15
1096,S1,NaN,UGN74788,NaN,SARS-CoV-2,synthetic construct,sggglqtpggglglvckapgfsiggyimhwvrqtpgkgleyvagidagggvtwygaavkgratisrdngqstvrlqlndlraedtgiyycarstgsdyydwnyageigawghgtevivssggggsggggsggggsaltqpssvsanpgetvkitcsgggsssyygwyqqkspggapvtviysntgrpsdipsrfsgsksgsthtltitgvqvddeavyycgsedssthdgifgagttltvlg,NaN,"Ge,S. et al.; Specific anti-SARS-CoV-2 S1 IgY-scFv is promising tools for COVID-19 diagnosis and treatment; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 S1 scFv antibody, partial [synthetic construct]",NaN,2022-03-15
1097,80R,NaN,2GHW_D,NaN,SARS-CoV,Homo sapiens (human),maevqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvssggggsggggsggggsettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevksglvpr,NaN,"Hwang,W.C. et al.; Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R; J. Biol. Chem. 281 (45), 34610-34616 (2006); 2006.",10.1074/jbc.M603275200,"Chain D, anti-sars scFv antibody, 80R",NaN,2022-03-15
1099,#16,NaN,7MFV_B,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfpvayktmwwyrqapgkerewvaaiesygikwtryadsvkgrftisrdnakntvylqmnslkpedtavyycivwvgaqyhgqgtqvtvsa,NaN,"Ahmad,J. et al.; Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes; bioRxiv (2021); 2021.",10.1101/2021.01.27.428466,"Chain B, Synthetic Nanobody #16 (Sb16)",NaN,2022-03-15
1100,RE5D06,NaN,7ON5_A,NaN,SARS-CoV-2,Vicugna pacos (alpaca),egsqvqlvesggglvqpggslrlscaasgitldyyaigwfrqapgkeregvsrirssdgstnyadsvkgrftmsrdnakntvylqmnslkpedtavyycaygpltkygsswywpyeydywgqgtqvtvss,NaN,"Guttler,T. et al.; Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies; EMBO J 40 (19), e107985 (2021); 2021.",10.15252/embj.2021107985,"Chain A, Nanobody Re5D06",NaN,2022-03-15
1101,NaN,NaN,QZW25479,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqaggslrlscavsgagahrvgwfrrapgkerefvaaigasggmtnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeyiywgqgtqvtvss,NaN,"Zhang,J. et al.; Recombinant expression of a SARS-CoV-2 neutralizing nanobody in Trichoderma reesei; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 spike protein receptor-binding domain nanobody, partial [synthetic construct]",NaN,2022-03-15
1102,NaN,NaN,QYK30720,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1103,NaN,NaN,QYK30719,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1104,NaN,NaN,QYK30718,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpgdtavyycnadpylwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1105,NaN,NaN,QYK30717,NaN,SARS-CoV-2,synthetic construct,evqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvagitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1106,NaN,NaN,QYK30716,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1107,NaN,NaN,QYK30715,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasggifignamgwyrqapgkerelvatirniggttyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1108,NaN,NaN,QYK30714,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvaginwggdntyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1109,NaN,NaN,QYK30713,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpgdvgsdfdywgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"anti-SARS-CoV-2 nanobody, partial [synthetic construct]",NaN,2022-03-15
1110,RBD-SPECIFIC,NaN,QYF06674,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qlqlvesggglvqaggslrlscaasertfsggvmgwfrqrpgkerefvaairwngastfyadsvkgrftcsrdnakntgylqmnsltpedtavyycaravrtyassdyyfqertydywgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-03-15
1111,RBD-SPECIFIC,NaN,QYF06673,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qvqlvesggglvqpggtlrlscaasgftldyyaigwfrqapgkeregvscisgsggitnytdsvkgrftisrdnakntvylqmnslkpedtavyycapvshtvvagcafeawtdfgswgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-03-15
1112,RBD-SPECIFIC,NaN,QYF06672,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qvqlvesggglvqaggslrlscaasgrtytmgwfrqapgkerefvaamrwsdtdyadslkgrftisrdnannamylqmnslgpedtavyycaageawlarsthhydywgqgtqvtvss,NaN,Ma H et al.; Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain; J Virol (2021) In press; 2021.,10.1128/JVI.02438-20,"anti-SARS-CoV-2 RBD-specific nanobody, partial [Vicugna pacos]",NaN,2022-03-15
1115,VHH-72,NaN,6WAQ_C,NaN,SARS-CoV,Lama glama (llama),qvqlqesggglvqaggslrlscaasgrtfseyamgwfrqapgkerefvatiswsggstyytdsvkgrftisrdnakntvylqmnslkpddtavyycaaaglgtvvsewdydydywgqgtqvtvssgs,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies; Cell 181 (5), 1004-1015 (2020); 2020.",10.1016/j.cell.2020.04.031,"Chain C, nanobody SARS VHH-72",NaN,2022-03-15
1117,SDAB-5F8,NaN,QNA42481,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasgrqavvfgwfrqapgkgleavaaihvpaknryyadsvkgrftisrdnskntlylqmnslraedtavyycaahyefndfvwqgyssdywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-5F8, partial [synthetic construct]",NaN,2022-03-15
1118,SDAB-4D8,NaN,QNA42480,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasgnidstryhgwfrqapgkgleavaaikgvwpedyyadsvkgrftisrdnskntlylqmnslraedtavyycaadqyewwvpgevgpylywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-4D8, partial [synthetic construct]",NaN,2022-03-15
1119,SDAB-3F11,NaN,QNA42479,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasggnaaermagwfrqapgkgleavaaiyyakfgpyyadsvkgrftisrdnskntlylqmnslraedtavyycaaeafvqspysgshttkywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-3F11, partial [synthetic construct]",NaN,2022-03-15
1120,SDAB-2F2,NaN,QNA42478,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasglaqskwaygwfrqapgkgleavaaidvatgpwyyadsvkgrftisrdnskntlylqmnslraedtavyycaahhiptkhpafpdfrdywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-2F2, partial [synthetic construct]",NaN,2022-03-15
1121,SDAB-1E2,NaN,QNA42477,NaN,"SARS-CoV-2, Spike protein",synthetic construct,qvqlvesggglvqpggslrlscaasgadafviiggwfrqapgkgleavaaiawtdqheyyadsvkgrftisrdnskntlylqmnslraedtavyycaaqdsayikskgsrayeywgqgtqvtvss,NaN,"Yang,W. et al.; Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor-Binding Domain; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 nanobody sdAb-1E2, partial [synthetic construct]",NaN,2022-03-15
1125,KA1,NaN,MZ133804,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycaadpgdvgsdfdywgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone KA1 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
1126,K7.19,NaN,MZ133811,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone K7.19 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
1127,KC3,NaN,MZ133805,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvaginwggdntyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvssklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone KC3 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
1128,KC1,NaN,MZ133806,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasggifignamgwyrqapgkerelvatirniggttyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone KC1 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
1129,KA1.EP1,NaN,MZ133807,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone KA1.ep1 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
1130,KC3.EP5,NaN,MZ133809,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpgdtavyycnadpylwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone KC3.ep5 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
1131,K7.13,NaN,MZ133810,NaN,SARS-CoV-2,synthetic construct,qvqlvesggglvqaggslrlscaasgyifgrnamgwyrqapgkerelvaaitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycntdpapgnpllrypdfdywgqgtqvtvsseqkliseedl,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone K7.13 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
1132,7-10A,NaN,MMU73335,NaN,SARS-CoV,Mus musculus (house mouse),evklqqsgpdlvkpfqslsltctvtgysitsgyswhwirqfpgnklewmgyihysgsttynpslksrisitrdtsknqfflqlnsvttedtatyycvryyeyfdywgqgttvtvssggggsggggsggggsdieltqspatlsvtpgdrvslscrasqsisdylhwyqqkshesprllikyasqsisgipsrfsgsgsgsdftlsinsvepedvgvyycqnghsfpftfgsgtkleikr,NaN,"Lamarre,A. et al.; A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice; Eur. J. Immunol. 27 (12), 3447-3455 (1997); 1996.",NaN,"Mus musculus single chain Fv antibody fragment scFv 7-10A mRNA, partial cds",NaN,2022-03-15
1133,KC3.EP3,NaN,MZ133808,NaN,SARS-CoV-2,synthetic construct,evqlvesggglvqaggslrlscaasgfifgrnamgwyrqapgkerelvagitrggstyyadsvkgrftisrdnakntvylqmnslkpedtavyycnadpyfwefdswgqgtqvtvsseqklaaahkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgkgshhhhhhkldykdhdgdykdhdidykddddk,NaN,"Zupancic,J.M. et al.; Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis; Cell Chem Biol (2021) In press; 2021.",10.1016/j.chembiol.2021.05.019,"Synthetic construct clone KC3.ep3 anti-SARS-CoV-2 nanobody gene, partial cds",NaN,2022-03-15
